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USE OF ANTIMICROBIALS AND CEPHAMICIN RESISTANCE IN COMPANION ANIMALS 
 
Objectives: This work includes two separate studies. In study 1 the aim was to investigate 
the use of antimicrobials in companion animals in Portugal while in study 2 the objective was 
to evaluate and characterize the prevalence of blaCMY-2 gene in Enterobacteriaceae and the 
phylogenetic relatedness among plasmids from companion animals and humans. 
Materials and Methods: In study 1 in order to understand the patterns of antimicrobial 
prescription a national survey was submitted to veterinarians. In study 2 plasmids harboring 
blaCMY-2 were transferred into GeneHog® E. coli by electroporation and typed by S1 
endonuclease pulsed-field gel electrophoresis, PCR-based replicon typing, and plasmid 
multilocus sequence typing (pMLST). 
Results: In study 1, the use of amoxicillin-clavulanate (28%) and enrofloxacin (18%) were the 
most common antimicrobials used in dogs and cats, whereas clindamycin (3%) cefovecin 
(2%) and pradofloxacin (2%) were the less prescribed. In study 2, twenty three blaCMY-2 
genes were plasmid encoded. Replicon typing demonstrated that from animal isolates, 
thirteen isolates were IncFII plasmids, five isolates were IncI1 plasmid, one isolate carried an 
A/C plasmid and the remaining isolate was non-typeable by PBRT. Regarding human 
isolates, one isolate was IncFII, one was IncI1 and the third isolate was also non-typeable. 
IncI1 blaCMY-2 plasmids showed that three were sequence type (ST2), three were non-
typeable and fourteen IncFII plasmids were F2;FIA-;FIB- by pMLST.  
Conclusions and Clinical Importance: This work showed that in order to understand how 
antimicrobials are prescribed, further studies and implementation of a surveillance system for 
antimicrobial usage in these species would be recommended. Plasmid encoded resistant 
genes are an important factor for selection and dissemination of genes such as blaCMY-2. The 
transmission of resistant genes in humans and animals is due to plasmid encoding which is 
of great concern, and further research is still necessary to understand about the mechanisms 





















USO DE ANTIMICROBIANOS E RESISTÊNCIA ÀS CEFAMICINAS EM ANIMAIS DE 
COMPANHIA 
  
Objetivos: Este trabalho inclui 2 estudos. O objetivo do primeiro estudo consistiu em 
investigar o uso de antimicrobianos em animais de companhia em Portugal enquanto no 
segundo estudo, o objetivo consistiu na análise e caraterização da prevalência do gene 
blaCMY-2 em Enterobacteriaceas, ao mesmo tempo que pretendeu determinar a semelhança 
filogenética dos respetivos plasmídeos, em animais e humanos. 
Materiais e Métodos: No estudo 1, para compreender os hábitos de prescrição de 
antimicrobianos em Portugal foi realizado um inquérito nacional aos Veterinários. No estudo 
2, os plasmídeos com o gene blaCMY-2 foram transferidos para uma célula electrocompetente 
GeneHog® E. coli por electroporação, e caraterizados por S1 endonuclease pulsed-field gel 
electrophoresis, PCR-based replicon typing e plasmid multilocus sequence typing (pMLST). 
Resultados: No estudo 1, os antimicrobianos mais utilizados em cães e gatos foram a 
amoxicilina/acido clavulânico (28%) e enrofloxacina (18%). Clindamicina (3%), cefovecina 
(2%) e pradofloxacina (2%) foram os menos utilizados em ambas as espécies. No estudo 2, 
vinte e três genes blaCMY-2 estavam codificados em plasmídeos. De acordo com o método 
replicon typing, os isolados de origem animal, treze pertenciam ao plasmídeo IncFII, cinco 
estavam codificados no plasmídeo IncI1, um estava presente no plasmídeo A/C e um 
isolado foi considerado “non-typeable”. Dos 3 isolados humanos, 1 estava incorporado num 
plasmídeo IncI1, 1 estava inserido no plasmídeo IncFII e o terceiro foi considerado “non-
typeable”. Pelo método pMLST, os plasmídeos IncI1 foram caraterizados como ST2, e três 
foram considerados “non-typeable”. Catorze plasmídeos IncFII foram caraterizados como 
sendo F2;FIA-;FIB-. 
Conclusões e Importância Clínica: Para compreender os hábitos de prescrição de 
antimicrobianos, seriam recomendáveis estudos complementares e a implementação de um 
sistema de monitorização para o consumo de antimicrobianos nestas espécies. A presença 
de genes de resistência em plasmídeos é um fator importante para a seleção e 
disseminação de genes como o gene blaCMY-2. A transmissão destes genes em humanos e 
animais é mediada por plasmídeos, o que é preocupante. Investigação contínua é pois 
necessária para entender quais os principais mecanismos que conduziram à disseminação 
de bactérias com genes de resistência no mundo. 
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During the World War II the production and use of penicillin was implemented for the first 
time as a response to treat the war causalities. In the last stage of this war the lyophilized 
preparations of penicillin were made available for veterinarians who reconstituted the 
antibiotic with saline for intramammary infusions to treat bovine mastitis. This fact 
represented a significant advance because penicillin proved to be more effective than 
treatments previously available for dairy animals. The variety of antibiotics, the routes of 
administration and the reasons for their use expanded during the period between 1950 and 
1960 (Gustafson & Bowen, 1997). 
Antimicrobials are medicines that kill or inactivate microbes. They include antibiotics, which 
are used against bacteria. After being exposed to an antimicrobial repeatedly, microbes can 
undergo changes that stop them being killed or inactivated by the treatments. This is known 
as antimicrobial resistance and is a growing problem in human and veterinary medicine. 
During the last decade a number of events have concerned the scientific community and 
increased the awareness of public health issues related to antimicrobial resistance. For 
example, the emergence of extended spectrum β-lactamases (ESBLs) it is a concern to 
human health due to the possibility of transfer of resistance genes across bacteria 
populations. The risks for humans related to antimicrobial resistance in animals are not 
circumscribed to foodborne risks only (European Medicine Agency [EMA], 2009a). When the 
microorganisms become resistant to most antimicrobials they are often referred to as 
“superbugs”. One the issue is that bacteria become resistant to critically important 
antimicrobials (World health Organization [WHO], 2011).  To address the need for universal 
terms for the various degrees of antimicrobial resistance, the following definitions were 
suggested. A pandrug resistant (PDR) isolate is designated as resistant to all available 
classes of antimicrobials, while the definition of extensive drug resistance (XDR) refers to a 
pathogen which is resistant to all but one or two classes. A strain is considered a multidrug 
resistant (MDR), if an isolate is resistant to three or more classes of antibiotics (β-lactams, 
aminoglycosides, fluoroquinolones, sulfonamides, and tetracyclines) (Falagas & 
Karageorgopoulos, 2008). 
The impact of antimicrobial use and possible misuse in animals as a public health issue is 
focused on food-producing animals mainly. However there are not many studies about the 
use of antibiotics in companion animals. The direct contact with pets makes it possible for the 
transference of resistant genes between companion animals and humans to occur. It is 
necessary to control and monitor the antimicrobial use in animals in order to avoid the 
increase of antimicrobial resistance. The European commission established an “Action plan 






promote antimicrobial surveillance in the different sectors involved actions regarding 
research and developing of novel antimicrobials (European Commission, 2011). The 
European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) project was started 
in 2010 by the European Medicines Agency (EMA). The aim of the project is to collect 
information every year on the use of antimicrobials agents from Europeans state members. 
This information is considered critical in order to monitor and identify risk factors associated 
with antimicrobial usage in animals. 
The awareness of this problem, together with the increase of antimicrobial resistance among 
companion animals and the interest by the author in this area led to this research project. 
The author aims to determine and characterize the resistance in Enterobacteriaceae to 
cephamycin in order to contribute to a better understanding of the mechanisms of 
development of antibiotic resistance. By understanding these mechanisms it can be possible 
to undertake new strategies to fight antibiotic resistance. The author also evaluates the use 
of antimicrobial agents in companion animals in Portugal through a national survey which 
was online during the time of the training period. The first part of this document will include a 
literature review of the main topics. The second part refers to the studies developed including 
its main goals, materials and methods, results, discussion and concluding remarks of this 
study. The terms antimicrobial and antibiotic, Rep type and Inc group to describe plasmids 
are used interchangeably in this thesis. 
 
1.1. Training period  
To accomplish the project, the author took a training period of approximately six months in 
two different locations. The first place was at the Laboratory of Antimicrobial Resistance and 
Biocides, Faculty of Veterinary Medicine, University of Lisbon, Portugal (FVM-UL) from 
September 20th to December 15th 2012, the remaining period was undertaken at 
LLP/Erasmus Program in the Microbiology Laboratory of the Faculty of Life Sciences, 
University of Copenhagen (KU-SUND) from January 10th to April 30th 2013, under the 































2. Literature Review 
 
2.1. The family Enterobacteriaceae  
2.1.1 Typical characteristics 
The family Enterobacteriaceae is considered to be the most important family which can 
cause a variety of community and nosocomial infections (meaning that are acquired in 
hospital environment) in humans such as septicaemia, urinary tract infections (UTI), 
pneumonia, cholecystitis, cholangitis, peritonitis, wound infections, meningitis, and 
gastroenteritis. Enterobacteriaceae falls within the domain Bacteria, phylum Proteobacteria, 
class Gammaproteobacteria, and order Enterobacteriales. In Table 1 are listed the most 
common genera and species belonging to this family. The members of this family are gram-
negative, rod-shaped, non-spore-forming facultative anaerobes that ferment glucose and 
other sugars, reduce nitrate to nitrite, and produce catalase but do not produce oxidase 
(Donnenberg, 2010). 
 
2.1.2. Natural habitat 
 Most Enterobacteriaceae are designated as enteric because the main habitat of most of 
them is the lower gastrointestinal tract of animals and humans, but the environment can also 
be a reservoir (Farmer, Boatwright & Janda, 2008). In large intestine there is a complex and 
dynamic interaction with high densities of living bacteria, which achieve concentrations of up 
to 1011 or 1012 cells/g in the luminal contents (Guarner & Malagelada, 2003). 
 
 Table 1 - Important genera and species of the family Enterobacteriaceae and most common type of 
infections (adapted from Abbott, 2008; Farmer et al., 2008; Nataro, Bopp, Fields, Kaper  & Stockbine, 
2008; Donnenberg, 2010). 
 
 
Genus Species Common type of infections 
Citrobacter Freundii UTIs, pneumonia, meningitis, septicaemia, wound infections 
Enterobacter cloacae, aerogenes UTIs, pneumonia, septicaemia, wound infections 
Escherichia  Coli UTIs, diarrhoea, septicaemia, meningitis 
Klebsiella pneumonia, oxytoca UTIs, pneumonia, septicaemia 
Morganella Morganii UTIs, septicaemia 
Proteus mirabilis, vulgaris UTIs, pneumonia, septicaemia, meningitis, wound infections 
Salmonella Enterica diarrhoea, typhoid fever, septicaemia, UTIs, osteomyelitis 
Serratia Marsecens UTIs, pneumonia, wound infections, septicaemia 
Shigella Dysenterii diarrhoea, dysentery 






2.1.3. Cell wall structure 
The structure from gram-negative bacteria is different from gram-positive; gram-negative 
bacteria cell wall is composed of a thin peptidoglycan layer, also named as murein 
(Beveridge & Graham, 1991; Donnenberg, 2010). The murein consists of alternating N-
acetylglucosamine and N-acetylmuramic acid amino sugars joined by β-1,4 linkages, with a 
short peptide composed of L-alanine, D-glutamic acid, L-meso-diaminopalmelic acid, and D-
alanine attached to the carboxyl group of the muramic acid (Donnenberg, 2010).  
The periplasmatic space ranges from 20%- 40% of total cell volume in a gram-negative 
bacteria, and is considered an integral compartment of the gram-negative cell wall (Stock, 
Rauch & Roseman, 1977; Beveridge, 1999). Together the plasma membrane and the cell 
wall (outer membrane, peptidoglycan layer, and periplasm) constitute the gram-negative 
envelope (Beveridge & Graham, 1991). The envelope is responsible for maintaining the 
shape and osmotic stability of the cell; however in the replication and elongation process of 
















2.2. Principals genera from Enterobacteriaceae family 
2.2.1. Escherichia coli 
Escherichia coli are the most important bacteria in the normal microbiota of humans and 
animals. It colonizes the gastro intestinal tract within hours after birth and there is a mutual 
relationship (symbiotic) between host and bacteria. However if the immune system or if the 
gastrointestinal barriers are compromised some strains can cause disease in gastro 
intestinal tract or urinary system for example (Nataro & Kaper, 1998). E. coli and Klebsiella 

















community-onset bacterial infections in humans (Paterson, 2006). The regular presence of E. 
coli in the human intestine and faeces has led to tracking the bacterium in nature as an 
indicator of faecal pollution and water contamination (Goyanes et al., 2007; Todar, 2008).  
 
2.2.2. Proteus spp. 
The two species most representative of this genus are: P. mirabilis and P. vulgaris which 
were both described in 1885 by Hauser. He noted the swarming colonies nature and 
classified them according to their ability to liquefy gelatine (O’Hara, Brenner & Miller, 2000). 
This swarming ability is related to the flagella which translocate very fast along the plates, 
and this characteristic allows then to differentiate from other Enterobacteriaceae. The 
genus Proteus spp. are lactose negative and motile (Donnenberg, 2010). 
Bacteria of the genus Proteus are a part of the commensal flora of the intestinal tract from 
humans and animals (O’Hara et al., 2000; Giammanco, Pignato, Grimont, Grimont & 
Giammanco, 2011) . P. mirabilis and P. vulgaris account for the majority of clinical isolates 
from this genus, acting also as opportunistic pathogens causing primary and secondary 
infections (Donnenberg, 2010; Giammanco et al., 2011). 
 
2.2.3. Klebsiella spp. 
The genus Klebsiella was named by Trevisian in 1885 to honour microbiologist Edwin Klebs 
(Brisse, Grimont & Grimont, 2006). Klebsiella spp. is ubiquitous in nature, can be found in the 
environment (water, soil, and plants) but also in the mucosa from humans and animals. 
Klebsiella pneumoniae is the most important species of the genus and is responsible 
together with Klebsiella oxytoca for 8% nosocomial bacterial infections in Europe (Podschun 
& Ullmann, 1998). 
 
2.2.4. Enterobacter spp. 
The genus Enterobacter includes 14 species, Enterobacter aerogenes and Enterobacter 
cloacae are by far the most important and relevant pathogens in humans among the genus 
Enterobacter.  Enterobacter spp. is considered an opportunistic pathogen, and recently has 
become an important cause of nosocomial  infections (Sanders & Sanders, 1997). 
 
2.2.5. Other Genus 
Other important Enterobacteriaceae species are: Salmonella spp., Citrobacter spp., Shigella 
spp. and Serratia spp. Salmonella is a facultative intracellular pathogen acquired by 
consumption of water and/or contaminated food. In contrast to other pathogens Salmonella 
spp. requires a large number of genes to become virulent (Groisman & Ochman, 1997). The 






is subdivided into over 2,000 serovars, and Salmonella bongori. The most important serovars 
of S. enterica, are: S. typhi, which is responsible for systemic infections and typhoid fever 
infecting only humans; and S. typhimurium, which is a leading cause of gastroenteritis in 
human and other mammalian species increasing the incidence of non-
typhoid Salmonella infections worldwide (McClelland et al., 2001). 
The genus Citrobacter spp. includes twelve species and is an important cause for 
opportunistic infections. Citrobacter species are commonly found in water, soil, food, and the 
intestinal tracts of animals and humans (Shih, Chen, Chang, Luh, & Hsieh, 1996; 
Donnenberg, 2010). 
In 1940, four species of the new genus Shigella spp. were recognized by Boydii as the cause 
for dysenteric disease in humans. Shigella and E. coli have always been considered to be 
very closely related, but E. coli strains became a different genus due to differences in 
medical significance (Lan & Reeves, 2002). 
Ten species are known to belong to Serratia genus and the most important species are: S. 
marsecens which can be differentiated from other bacteria by producing a red pigment 
named Prodigiosin; and S. liquefascens. These species can be found in water, mammals 
and also in hospitalized patients (Grimont & Grimont, 2006). 
 
2.3. Clinical significance of Enterobacteriaceae 
The family Enterobacteriaceae as referred previously is indeed the most important family 
which colonize the gastrointestinal tract since early age and coexist with animals and 
humans with mutual benefits for decades. In many situations the infections caused by these 
species are nosocomial. As it is shown in table 1, Enterobacterial strains are responsible for 
a variety of clinical situations such as urinary tract infection, pneumonia, and sepsis (Kaper, 
Nataro & Mobley, 2004). 
The species Escherichia coli causes diverse intestinal and extraintestinal diseases by means 
of virulence factors, named serotypes. The main causes of diarrhoea in animals and humans 
is triggered by enterotoxigenic E. coli (ETEC) and entero haemorrhagic  E. coli  (EHEC) 
(Kaper et al., 2004). E. coli is also considered an important  pathogen in canine UTIs (Feria, 
Ferreira, Correia, Gonçalves & Caniça, 2002 ). 
Klebsiella spp. is an opportunistic ubiquitous pathogen and is a major cause of nosocomial 
infections. The targets are usually immune-compromised individuals that are hospitalized 
with chronic diseases. Klebsiella pneumoniae is responsible for most of the outbreaks in 
health care facilities. This species is also involved in urinary tract infection, pneumonia, 
septicaemia and soft tissue infections (Podschun & Ullmann, 1998; Struve & Krogfelt, 2004). 
In animals it can act as an opportunistic pathogen it has been implicated in cases of mastitis 






dogs (Roberts, McClain, Hansen, Currin & Howerth, 2000). The importance of Klebsiella is 
based on the increasing reports of clinical situations caused by multiresistant strains capable 
of producing extended spectrum β- lactamases (Podschun & Ullmann, 1998).  
Of the Yersinia genus three species Y. pestis, Y. enterocolitica and Y. pseudotuberculosis 
are well known animal and human pathogens. Pathogenic strains of Y. enterocolitica and Y. 
pseudotuberculosis cause yersiniosis, an acute enteric disease, in humans and animals 
(Stamm, Hailer, Depner, Kopp & Rau, 2013). Y. enterocolitica is regarded as a significant 
food-borne pathogen. Besides food producing animals, companion animals are also 
considered a reservoir  for human Yersinia infections (Stamm et al., 2013). Y. pestis is 
responsible for the plague, a zoonotic disease transmitted to human through a vector (fleas) 
(Linde, Neubauer, Meyer, Aleksic & Lehn, 1999). In contrast to other Enterobacterea, 
Yersinia pestis circulates in the bloodstream, lymphatic vessels and organs like spleen and 
liver, and may contact with Enterobactereaceas when reaching the bloodstream. To date 
there have been 3 major plagues and a high number of casualties (Galimand, 1997). 
The family Enterobacteriaceae is the most important and relevant in clinical therapy because 
it is a common source of infections in animals, community and hospitals spreading easily 
between humans (Pitout, 2008a). These bacteria also have the ability to acquire new genetic 
material through horizontal gene transfer (HGT), mediated by plasmids or transposons. This 
combination represents an important issue regarding the emergence of multidrug resistance 
in Enterobacteriaceae and lights up the possibility of interspecies transfer of resistance 
determinants (Wise et al., 1998; Nordmann, Dortet & Poirel, 2012). 
 
2.4. Antimicrobials – The era of antimicrobials 
“One sometimes finds what one is not looking for” - Alexander Fleming 
The general term “antibiotic era” is usually associated with the names of Paul Ehrlich and 
Alexander Fleming. Ehrlich’s wanted to find a drug against syphilis which targeted only the 
source of infection caused by the spirochete Treponema palladium. Syphilis was considered 
an endemic disease and almost incurable at the time. In 1909 after several  trials with rabbits 
an effective compound was discovered, marketed under the name Salvarsan, and for many 
years was the most prescribed drug until its replacement by penicillin (Aminov, 2010). 
The introduction of antibiotics in the 1940s was considered as one of the greatest 
advances/achievements in therapeutic medicine for treating and preventing infectious 
diseases in human medicine. An antibiotic can be defined as a natural compound which is 
produced from fungi, bacteria and other microorganisms that can kill or inhibit the growth of 
bacteria, while the term antimicrobial refers to a group of substances, natural or synthetic 
which includes also the antibiotics, antifungals, antiprotozoals and antivirals (WHO, 2011). 






or synthetic when the chemical scaffolds were used later to create new generations of 
clinically useful antibiotics by chemical modification (Peláez, 2006). The first antibiotic named 
penicillin was discovered by Alexander Fleming in 1928 when he observed that a common 
mould (Penicillium notatum) produced a substance that inhibited the growth of colonies of 
Staphylococcus spp. (Ligon, 2004). 
Howard Florey and Ernst Chain, both part of an Oxford team, were the scientists who in 1940 
were able to purify penicillin for clinical testing. The period from the 1950s throughout the 
1970s is defined as the golden era of discovering new classes of antimicrobial agents 
(Aminov, 2010). Since year 1993 there has not been many new classes of antimicrobials 
developed by industry and that we might face a shortage of therapeutic options against multi-
resistant bacteria. That is well supported by Figure 2. 
Nowadays there is growing concern about the increase of antibiotic resistance increase 
worldwide. The use of antibiotics is considered to be the main factor for pathogenic bacteria 
growth which has led to the dissemination of resistant bacteria and resistant genes. This 
situation applies to both human and veterinary practice, since antimicrobials are used for 
similar purposes (e.g. prophylaxis therapy of infectious diseases) in humans and animals. 
This can lead to the increase of levels of resistance traits in pathogenic and commensal 
bacteria. Resistant bacteria can infect humans by direct contact or via food products of 
animal origin (Van den Bogaard & Stobberingh, 2000). So far many studies have 
emphasised mainly in food producing animals. To decrease the risk of transmission of 
antimicrobial residues and pathogens through the food chain some countries have developed 
















Sulfonamides discovered (1932) 
Penicilin discovered (1928) Penicilin introduced (1942) 
Streptomycin discovered (1943) 
Bacitracin disc. (1943) 
Cephalosporin disc.  (1945) 
Cloramphenicol  disc.(1947) 
Neomycin disc. (1949) 
Methicilin introduced (1942) 
Ampicilin int. (1943) 
Gentamicin discovered(1943) 
Cephalosporin int.(1945) 
Vancomycin int.l (1964) 
Doxycicline int. (1966) 
Clindamycin reported (1697) 
Oxitetracycline discovered (1950) 
Erytromicin  disc. (1952) 




Imipenem int. (1987) 
Ciprofloxacin int. (1987) 
Linezolid introduced (2000) 
Tigecycline int. (2005) 
Figure 2 - Discovery of antimicrobials (adapted from http://amrls.cvm.msu.edu/pharmacology/historical-perspectives/the-
golden-age-of-antibacterials). 
 
Rifampicin introduced (1971) 
Cephamicins discovered (1972) 
Amikacin introduced (1976) 
Azytromicin introduced (1993) 






2.4.1. Classification of antibacterial agents 
 Antibacterial agents can be classified according to their mechanism of action (how 
antimicrobial growth is supressed) and by spectrum of activity. The five main target sites of 
antimicrobial agents are: (i) cell wall synthesis, (ii) protein synthesis, (iii) nucleic acid 
synthesis, (iv) metabolic pathways, and (v) cell membrane functions (Figure 3) (Tenover, 
2006; Maddison, 2009). Antibacterial drugs that act by inactivating the wall synthesis include 
the penicillins, cephalosporins and vancomycin. Aminoglycosides and tetracycline inhibit 
protein synthesis by binding to the ribosomal subunit 30S, while macrolides and 
chloramphenicol bind to the 50S ribosomal subunit to inhibit protein synthesis. 
Fluoroquinolones antimicrobial agents disrupt the DNA synthesis whereas sulphonamides 













Antibacterial agents can be classified as bactericidal or bacteriostatic. This classification is 
used mainly for clinical purposes and is not consistent to all bacteria. The ability of an 
antimicrobial agent to inhibit or kill a microorganism is relative and depends on the bacteria. 
For example chloramphenicol inhibits the growth (bacteriostatic) of E. coli while it kills 
(bacteriocidal) Haemophilus influenza (Maddison, 2009). Bacteriostatic agents inhibit 
bacterial growth as long as the drug concentration is above the minimal inhibitory 
concentration (MIC). Tetracycline, chloramphenicol and sulphonamides are examples of 
bacteriostatic agents. Bactericidal agents e.g. aminoglycosides, cephalosporins, 
fluoroquinolones, metronidazole, penicillins and potentiated sulphonamides kill the bacteria 
and are preferred in infections in which  the host cannot control or eradicate the infection due 
to location of the infection itself or due to the compromised immune status of the host. 
Bactericidal agents can also be further classified as time-dependent (penicillins and 
cephalosporins, both slow bactericidals), or concentration-dependent drugs. For bactericidal 
antibiotics, plasma levels of antibiotic concentration must be above the MIC as long as 
Inhibition of protein synthesis 
Inhibition of DNA 
synthesis 
Inhibition of cell wall synthesis 






possible (each 24 hours of treatment). In contrast, for concentration-dependent drugs 
(aminoglycosides and fluoroquinolones), the higher the plasma peak is achieved, the greater 
the proportion of bacteria killed. The peak concentrations, the area under the plasma 
concentration versus time curve are important for bactericidal success (Maddison, 2009). In 
order to a better understanding of antibiotic activity it is necessary to determine some 
important parameters as illustrated in Figure 4. The first parameter, time at which 
concentration is above the MIC (t > MIC), is related to bactericidal effects over time. It refers 
to the time in which the drug is above the MIC and is dependent on the half-life, dosage, 
frequency of administration of the drug over a certain time period. The parameter 
corresponding to the ratio peak plasma concentration (Cmax)/MIC, it is the maximum 
concentration of a certain drug in the plasma, relates bactericidal effects with concentration, 
and is mainly dependent on the unit dose and the volume of distribution of the drug. The last 
parameter, area under the concentration-time curve (AUC)/MIC, combines both types of 
effects, because it refers  to the total amount of drug to which bacteria are exposed over the 
time period, and is directly related to the total dose given during that period and inversely 
proportional to the drug clearance (Bambeke, Barcia-Macay, Lemaire &  Tulkens, 2006). 
 
Figure 4 - Antibacterial concentration vs. time graph illustrating pharmacokinetic and   














The effectiveness of individual drugs against the isolated organism is categorized according 
to the new ISO 20776-1 standard using the following categories: "Susceptible", 
“Intermediate” and “Resistant” depending on the MIC value. The MIC is defined as the 
minimum concentration of an antibiotic that is able to prevent the further growth of the 
infectious organism in vitro  (Rodloff, Bauer, Ewig, Kujath & Müller, 2008). Susceptible (S), a 



































concentration of this drug that is associated with a high rate of therapeutic success. 
Intermediate (I), the sensitivity of a bacterial strain to a given antibiotic is said to be 
intermediate when it is inhibited in vitro by a concentration of this drug that is associated with 
an uncertain therapeutic effect. Resistant (R), a bacterial strain is said to be resistant to a 
given antibiotic when it is inhibited in vitro by a concentration of this drug that is associated 
with a high possibility of therapeutic failure. The European Committee on Antimicrobial 
Susceptibility testing (EUCAST) in order to harmonise and define breakpoints provides 
clinical breakpoints and epidemiological cut-off values (ECOFF). The ECOFF are used in 
clinical breakpoint development and as a sensitive indicator of resistance development in 
surveillance studies (European Committee on Antimicrobial Susceptibility testing [EUCAST], 
2007).  
 
2.5. β-lactam antibiotics 
2.5.1. General structure and functions 
The β-lactam bactericidal antibiotics, including – penicillins, cephalosporins, monobactams 
and carbapenems are one of the most widely used group of antimicrobials due do their 
safety, low cost, ease of delivery, minimal side effects and high efficacy. β-lactam antibiotics 
are grouped together based upon a shared structural feature (Wilke, Lovering & Strynadka, 
2005). β-lactam is a generic name for all β-lactam antibiotics that contain a β-lactam ring, a 
heteroatomic ring structure, consisting of three carbon atoms and one nitrogen atom (Wilke 
et al., 2005). 
This group represents 60% of all antimicrobial used by weight and is used to treat infections 
caused by gram-negative bacteria and gram-positive, in human medicine (Livermore & 
Woodford, 2006). In veterinary medicine, different substances from the penicillin family, first 
to fourth generation cephalosporins and β-lactamase inhibitors are recommended for the 
treatment of companion animals according to the animal species involved and the underlying 
disease (Guardabassi, Jensen & Kruse, 2008; Smet et al., 2010). 
 
2.5.2. Mechanism of action 
β-lactam antibiotics inhibit the growth of bacteria by inactivating enzymes called penicillin-
binding proteins (PBPs), located in the bacterial cell wall which are involved in the third stage 
of cell wall synthesis (Poole, 2004). β-lactam antibiotics normally interfere with this process 
by reacting covalently with the active site serine to form a stable acyl-enzyme preventing the 
peptidoglycan synthesis (Hujer et al., 2005). In contrast to gram-positive bacteria, in gram-
negative the peptidoglycan it is a thin layer between the cell wall and the cytoplasmic 
membrane. The antibiotic β-lactam must diffuse across the outer membrane of the gram-






reaching its PBP targets, which lie on the outer surface of the cytoplasmic membrane  
(Livermore & Woodford, 2006). 
 
2.5.3. Penicillin 
Penicillin was discovered in 1928 by Alexander Fleming and has activity against gram-
positive and gram-negative bacteria (Tipper & Strominger, 1965). This class is considered 
the best known and first β- lactam antibiotic. All penicillin have a β-lactam, a thiazolidine ring 
and a side chain R group which is distinguishable between penicillins (Figure 5) (Baldo, 
1999). In 1940 a large amount of penicillin was produced from cultures of Penicillium 
notatum. Several years after the first penicillin, penicillin G became available; however, it had 
some limitation such as instability in gastrointestinal (GI) and was not very effective against 
important gram-negative bacteria (Chambers, 2010).  
 
2.5.4 Cephalosporins 
This first isolation of Cephalosporium acremonium culture was discovered in 1948 by 
Giuseppe Brotzw but only became commercially available in 1962 (Botana, Landoni & 
Martín-Jiménez, 2002). Researchers at the University of Oxford isolated cephalosporin C in 
1956 (Abraham & Newton, 1961). Some years after four classes of cephalosporins were 
produced (Botana et al., 2002). Cephalosporins of first generation have activity against gram-
positive bacteria such as Streptococcus, Corynebacterium, S. aureus e S. pseudintermedius 
and limited activity towards gram-negative bacteria, as it shown in Table 2. Enterococcus 
spp., Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) 
are resistant to these antibiotics. Cephalosporins are grouped into generations according to 
their spectrum of activity against gram-negative bacteria (Donowitz & Mandell, 1988). The 
cephamycins differ from the true cephalosporin by the presence of a methoxy-group in the 
position 7 of the cephalosporin group but are grouped together and classified according to 
their in vitro spectrum activity and structural similarities. Cephamicins remain stable to many 




Monobactam antibiotics are a new class of β-lactam antibiotics. In contrast to penicillins or 
cephalosporins, monobactams have a monocyclic β-lactam structure and are produced by a 
range of bacterial species. Although these antibiotics exhibit poor antibacterial activity, they 
are highly stable to the action of β-lactamases produced by gram-negative bacteria (Sykes, 








Carbapenems are the class of β-lactam antibiotics with the broadest spectrum of activity 
(Nordmann et al., 2012). The activity includes many gram-positive, gram-negative and 
anaerobic bacteria; and no activity is recognized towards Enterococcus faecium, methicillin-
resistant Staphylococcus aureus and Stenotrophomonas maltophilia. The increase of β-
lactamase resistance among Enterobacteriaceae led to the use of carbapenems widely, 
because they are stable to most β-lactamases including AmpC β-lactamases (Zhanel et al., 
2007). Carbapenems are a last resource against bacterial infections used mainly when the 














2.5.7. β-lactamase inhibitors 
The β-lactamase inhibition can be classified as either reversible or irreversible. Reversible 
inhibitors bind to an enzyme but activity may be restored after their removal. Irreversible 
inhibitors may be more effective than reversible inhibitors because the final outcome is the 
destruction of enzymatic activity. Specific irreversible inhibitors of β-lactamases include the 
clavulanic acid, the penicillanic acid sulfones sulbactam and aztreonam (Bush, 1988).  
These substances are used in the treatment of serious Enterobacteriaceae and penicillin-
resistant staphylococcal infections (Drawz & Bonomo, 2010). New compounds such as 
clavulanic acid and sulbactam exhibit low bactericidal activity when used alone but remain 
Figure 5 - Different structure of b lactam antibiotics: a) penicilin, b) cephalosporin, c) monobactam, d) 











effective against β-lactamases enhancing the activity of  β-lactam antibiotics, hence the 
name (Moosdeen, Williams & Yamabe, 1988). Clavulanic acid was isolated 
from Streptomyces clavuligerus and was the first β-lactamase inhibitor introduced worldwide. 
Clavulanate (the acid from the solution) had weak bactericidal activity but combined with β-
lactam antibiotics decreases the MIC values of some resistant bacteria (Reading & Cole, 
1977). Later penicillinate sulfones, e.g. sulbactam and tazobactam were introduced in the 
clinical practice. These 3 substances are effective against many susceptible organisms 
expressing class A β-lactamases, which are the most common (including CTX-M and the 
ESBL derivatives of TEM-1, TEM-2, and SHV-1); and are generally less effective against 
class B, C, and D β-lactamases (Bush, 1988; Buynak, 2006). The combination of amoxicillin 
with clavulanate was selected due to the similarity in pharmacokinetics between the two 
compounds. Any new β-lactamase inhibitors should have the following characteristics: the 
molecules must be capable of preventing hydrolysis of well-tolerated broad-spectrum β-
lactam antibiotic, preferably inexpensive penicillin; the pharmacokinetics of the two 
molecules should be similar; side effects should be minimal and mild; the molecules should 
not be good inducers of cephalosporinase activity. Ideally, one would like to have molecules 
with oral activity (Bush, 1988). 
The use of β-lactamase inhibitors remains effective in the empirical treatment of respiratory, 
intra-abdominal, skin and soft tissue infections in humans. The use of β-lactamase inhibitors 
instead of cephalosporins appears to reduce the emergence of resistance in pathogens. In 
Portugal, amoxicillin-clavulanate is the first line antimicrobial for UTI infection in dogs, which 
leads to a strong selection pressure for the emergence of resistant bacteria (Feria et al., 
2002). Similarly, their use may also curtail the emergence of other resistant pathogens such 







Table 2 - Spectrum of β-lactam antibiotics within their use in Veterinary and Human Medicine -: no activity, (+): limited activity, +: active (adapted from 













Penicillin - + ampicillin,  amoxicillin,  benzylpenicillin penicillin, ampicillin, amoxicillin 
First generation cephalosporins (+) + cephadroxil, cefapirin, cephalexin cefalozin 
Second generation cephalosporins  +  + cefaclor, cefamandole, cefuroxime cefuroxime, cefoxitin 
Third generation cephalosporins + + cefovecin, cefpodoxim, ceftiofur ceftriaxone, cefotaxime, ceftazidime 
Fourth generation cephalosporins + + cefquinome cefepime, cefpirome 
Monobactams + - not in use aztreonam 
 
Carbapenems + + imipenem, meropenem 
 






2.6. Antimicrobial resistance 
Resistance to an antibiotic typically develops from its use according to Darwin´s principle: 
“survival of the fittest” (WHO, 2011). Antimicrobial resistance remains a global health 
concern and most countries have developed strategies to evaluate the level of resistance 
(Martins da Costa, Loureiro & Matos, 2013). This issue has emerged as a consequence of 
the selective pressure exerted by the overuse and misuse of antimicrobials in veterinary and 
human medicine. Furthermore, morbidity and mortality have increased in human medicine 
associated with resistant pathogens and thus failure therapeutic (Davies & Davies, 2010).  
Recently, the World Health Organization (WHO) published a report establishing the critically 
important antimicrobial for human medicine (annex 1). The problematic of antimicrobial 
resistance becomes crucial when pathogens become resistant to these antimicrobials. The 
criteria for inclusion were:  (1) sole therapy or one of few alternatives to treat serious human 
disease and (2) antimicrobial agents used to treat diseases caused by organisms that may 
be transmitted via non-human sources or diseases caused by organisms that may acquire 
resistance genes from non-human sources (WHO, 2007). Humans can acquire resistant 
pathogens or resistant genes of animal original directly from food consumption, direct contact 
with animals or through the environment (Rolain, 2013). In addition the use of the critically 
important antimicrobials should be minimised in animals to maintain/preserve the efficacy of 
these for treating human’s infections (Danish Small Animal Veterinary Association [SvHKS], 
2013). 
 
2.6.1. Use of antimicrobials in food-producing animals 
The introduction of antimicrobials in food-producing animals started in the 1940s to treat 
diseases and for growth purposes (Hammerum & Heuer, 2009).   
In 1951 it was first reported in California the effects of using streptomycin in turkeys and the 
emergence of streptomycin-resistant isolates from those animals (Starr & Reynolds, 1951). 
Since then, issues about the use of antibiotics are still questioned by the international 
community and professionals (Seiffert, Hilty, Perreten & Endimiani, 2013). The amount of 
antibiotics used at this time was considered higher than in human medicine. Addressing the 
rapid spread of antimicrobial resistant pathogens, Sweden was the first country to abandon 
the use of antibiotics as growth promoters in 1986 (WHO, 2011).  In The European Union 
(EU) these agents were banished in the 1th January 2006 (European Comission, 2005). The 
effects of discontinuation of antimicrobial agents as growth promoters in European countries 
decreased antibiotic resistance in animals, food products, and also in humans (Anderson, 
Nelson, Rossiter & Angulo, 2003).  
The overall amount of antibiotics used is not clearly known because the data provided from 






reported by weight of active ingredient or total weight of feed additives. Another important 
aspect is that the data reports to both companion animals and food producing animals 
regarding drugs licensed for multispecies used (EMA, 2009b, 2013). According to the 
European Medicine Agency (EMA), there is a slight downward trend for use of antimicrobials 
in animals in all countries. However, use of β-lactams antibiotics is increasing slightly (EMA, 
2009b). The information on use and consumption of cephalosporins in the EU is not available 
for all members, and often the data includes β-lactam antibiotics (including ampicillin, 
benzylpenicillin). Furthermore, when the data provides the use of penicillins and 
cephalosporins separately, are not divided by generations. Currently there are specific 
recommendations on prudent use of cephalosporins in the EU. Nevertheless, monitorisation 
is needed on how the guidelines and recommendations are being implemented (Passantino, 
2007). 
According to data published in Portugal, the total amount of antimicrobial sold was 162,564 
tons of active substance during the year of 2011 (includes all animal species). Doxycycline 
and amoxicillin were the most used antimicrobials. In cattle, florfenicol was the most common 
antimicrobial sold, and doxycycline for the swine (Direcção Geral Aimentação e Veterinária [ 
DGAV ], 2011). 
 
2.6.2. Use of antimicrobials in companion animals 
Due to the use of antimicrobials that are critical to human medicine, the risk of antimicrobial 
resistance emergence and inter-species clonal spread, the awareness in the last few years 
of the veterinary community for the potential implications for public health has increased 
(Martins da Costa et al., 2013). 
Systematic surveillance of the occurrence of resistant bacteria from food animals, food and 
humans has been established and annually reports are published in European Food Safety 
Authority (EFSA). In contrast, data is rare regarding extent and characteristics of 
antimicrobial resistance among  bacteria from companion animals (Pedersen et al., 2007).  
The increasing number of reports on antimicrobial resistance in veterinary practice in addition 
to reports of multidrug pathogens led some countries to create guidelines to promote rational 
use of antimicrobial in veterinary practice. The Swedish Veterinary Association (SVA) 
developed guidelines in 2002, and countries like Denmark in 2013 followed their counterparts 
(SvHKS, 2013). In Sweden since 2006 a decrease in antimicrobial sales is clearly marked 
specially on aminopenicillins with clavulanic acid, cephalosporins and fluoroquinolones. This 
downward trend is explained by the application of guidelines and campaigns which led the 
veterinarians to change their prescription habits (SWEDRES-SVARM, 2012). According to 
the Danish Programme for surveillance of Antimicrobial Consumption and Resistance in 






decreased in veterinary medicine due to the reduction of cephalosporins usage. The 
information on companion animals follows an upwards trend since 2005 caused by the use of 
combination penicillins (DANMAP, 2012). According to this facts Sweden is clearly a classic 
example of how the combination of strong policies on prescribing and implementation of 
guidelines can improve the rational use of antibiotics. 
In the UK, a large amount of antimicrobial sales were for veterinary use  (Veterinary Medicine 
Directorate [VMD], 2012). The total sales amount of therapeutic antimicrobials in 2008 
decreased to 384 tonnes. In 2011, total sales have decreased by 101 tonnes to total 346 
tonnes. Tetracyclines, β-lactams (including penicillins) and trimethoprim/sulphonamides 
accounted for the majority of antibiotic active ingredients sold in veterinary medicinal 
products from 2006 to 2011 (VMD, 2012). The incidence of E. coli isolates from companion 
animals with patterns of resistance has increased over the last years to antibiotics commonly 
used to treat infections caused by this agent such as amoxicillin-clavulanate, cefpodoxime, 
enrofloxacin, and trimethoprim sulphonamide according to a study conducted in Denmark 
(Pedersen et al., 2007).  
Interestingly, pharmaceutical companies are not currently developing novel antibiotics 
because it is not cost effective for the drug companies. It is indeed critical to maintain the 
effectiveness of the antibiotic classes available by promoting a rational and prudent use 
(Coates & Hall, 2011). It is also important to create incentives for the research and 
development of new antimicrobials by industry (EMA, 2009a). 
In Portugal the only extended spectrum cephalosporin approved for dogs and cats is 
Cefovecina (Convenia©). In dogs and cats it is indicated for skin infections caused by S. 
pseudintermedius, Streptococci β-haemolytic, E. coli and/or Pasteurella multocida; and for 
urinary tract infections caused by E. coli or Proteus spp. (only in dogs) (Associação 
Portuguesa da Indústria Farmacêutica [Apifarma], 2011; EMA, 2012).  The use of third 
generation cephalosporins in human medicine in Portugal are cefetamet, cefixima, 
cefotaxime, ceftadizime e ceftriaxona and most can be acquired in a community pharmacy. 
(Infarmed, 2012). In a report published by DGAV in 2011, the most common antimicrobial 
used in dogs and cats was amoxicillin (DGAV, 2011). The term extra label drug use (often 
referred to as “off-label use”) was defined as the use in animals of a drug at an indication, 
dosage, frequency or route of target species (e.g. human drugs in animal species or a drug 
licensed for use in dogs in a cat) (Canadian Veterinary Medical Association [CVMA], 2010). 
In a recent report published by The European Surveillance of Veterinary Antimicrobial 
Consumption (ESVAC), for the majority of countries, penicillins (36% in tonnes) were the 
most sold veterinary antimicrobial agent, followed by 1st and 2nd-generation cephalosporins 






tablets (oral antimicrobials) and injectable antimicrobials are not included in this report (EMA, 
2013). 
 
2.6.3. Use of antimicrobial in humans 
There is a clear relation between the use of antimicrobials and antibiotic resistance which is 
increasing in southern countries but the prevalence in northern countries remains low. Data 
analysis is not consensual since national databases use different methodologies to classify 
antibiotics and measure their consumption (Goossens, Ferech, Vander Stichele & Elseviers, 
2005). In 2001, the European Commission funded the European Surveillance of 
Antimicrobial Consumption (ESAC) project, an international network of surveillance systems 
to collect comparable and reliable data on antibiotic use in Europe. The study conducted 
during the period 1997-2003 concluded that overall antibiotic use increased in most 
European countries, and penicillin was the most prescribed (Ferech et al., 2006). In another 
study by ESAC during the period 1997-2002 refers Portugal as the fourth consumer for 
antimicrobials in Europe with an increase of 10% in 2002 when compared with 1997.  
Penicillins were the most prescribed antibiotic in all countries analysed (Elseviers, Ferech, 
Vander Stichele & Goossens, 2007). In 2003 the study by ESAC reveals that Portugal was 
classified as the 4th consumer of antibiotics, and number one on fluoroquinolones usage 
(Ferech et al., 2006). Despite the downward trend in the last few years, Portugal still has a 
high consumption of antibiotics; and penicillin was the most prescribed agent, followed by 
macrolides, lincosamines, streptogramins and fluoroquinolones (Ferech et al., 2006). 
Cephalosporins are widely used in human medicine both in hospitals and community to treat 
septicaemia, and meningitis (Paterson & Bonomo, 2005). The total consumption in hospitals 
in 15 European countries in 2002 ranged from 1.28 to 3.89 defined daily doses (DDD)/1000 
inhabitants per day (Vander Stichele, Elseviers, Ferech, Blot & Goossens, 2006). In the 
same report an increase of third and fourth generation cephalosporin between 1997-2002 
was noted in all countries (Vander Stichele et al., 2006).  
In 2003 the total amount of antibiotics used in 34 countries European ranged from 3.89 to 
31.40 DDD/1000 inhabitants per day (Ferech et al., 2006). Cephalosporins from third and 
fourth generation were limited to patients with clinical conditions difficult to control. However, 
in three countries the use of these cephalosporins accounted for more than 40% of the total 
use. These differences between countries might be explained by a misuse of the antibiotics 
in hospitals (Coenen et al., 2006). Defined daily dose (DDD) is a measuring unit which 
defines an average maintenance dose per day for a drug used for its main indication in 






It is crucial in all of this process to have a multidisciplinary approach together with 
pharmaceutical companies, agencies, professionals in the area in order to accomplish: one 
world, one health. 
 
2.6.4. Prudent use guidelines 
Antimicrobials are vital agents in veterinary medicine, and due to the lack of alternatives (e.g. 
vaccines) cannot be replaced in a near future (Ungemach, Müller-Bahrdt & Abraham, 2006). 
In November 2000, the German Federal Veterinarians Association (BTK) published the 
guidelines for prudent use of antibacterial in animals in order to reduce the use of 
antimicrobials. The guidelines are an important source of information in which veterinarians 
should comply in order to preserve human and animal health. Numerous professionals 
groups have developed prudent use of guidelines for treatment of animal species according 
to the underlying cause of infection  (CVMA, 2000; Morley et al., 2005; American Veterinary 
Medical Association [AVMA], 2006; Ungemach et al., 2006). Overall the guidelines 
specifically outline the appropriate use of antibiotics. In the following a brief overview of the 
principles is given: 
 Preventive strategies, such as appropriate husbandry and hygiene, routine health 
monitoring, and immunization, should be emphasized. Other therapeutic options 
should be considered prior to the use of antimicrobials;  
 Prescription and extra label use of antimicrobials should always be performed by a 
veterinarian;  
 Therapeutic use of antimicrobials is only recommended in case of bacterial infection. 
Substances with narrow spectrum should be chosen whenever is possible and 
critically important antimicrobials in human medicine should be avoided. To choose, 
the antimicrobial culture and antimicrobial susceptibility testing should be performed 
to aid selection; 
 Therapeutic exposure to antimicrobials should be minimized by treating only for as 
long as needed for the desired bacteriological response; 
 Accurate records of treatment should be maintained and analysed the outcomes to 
evaluate effectiveness of therapeutic regimens. 
 
Therefore, antimicrobials can only be prescribed by a veterinarian and used by the owner 
according with the instructions (dosage, frequency of dosing and duration). The use of 
antimicrobials should be restricted for therapeutic and metaphylatic purposes. However in 
some cases of immunosuppressive situation or contaminated surgeries can be used as a 






characteristics: can be given intravenously to ensure a high plasma concentration; have few 
or no side-effects reported and should not increase the development of resistance (SvHKS, 
2013). 
 
2.6.5. Data collection methods 
There are several methods for collecting data on the use of antimicrobial drugs in animals. 
The choice of the method is according to the specific information required. To understand 
and monitor the consumption of antimicrobial in animals systematic information can be 
collected as sales data from the pharmaceutical industries, as in the Netherlands (Monitoring 
of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands [MARAN], 
2007), and the United Kingdom  (VMD, 2012); from pharmacies as in Sweden and Denmark 
(DANMAP, 2012; SWEDRES-SVARM, 2012). Countries like Norway and Finland use their 
wholesaler statistics. The sales data represents an advantage in those countries; however 
most European countries, (Portugal included) do not have any systematic surveillance on 
antimicrobial usage available (Kools, Moltmann & Knacker, 2008). 
Using the wholesalers or pharmacies data is useful when annually trends are analysed and 
allows comparing with international reality. This information can be comparable specially 
when using similar measuring units (e.g. kilograms) of the distributed antimicrobial. 
In Sweden and Denmark data is collected from all pharmacies and all of them belong to the 
National Corporation of Swedish Pharmacies. All antimicrobials for companion animals are 
only obtainable through a veterinary prescription. Therefore annual reports on antimicrobial 
surveillance are available (SWEDRES-SVARM, 2012). In Denmark the antimicrobial usage is 
controlled by the Danish VetStat® system which collects all the information from the 
pharmacies. Information such as animal species and dosage can be obtained by prescription 
data (DANMAP, 2012). 
As stated above, the information provided by wholesalers or pharmacies gives important 
information concerning the usage of antimicrobial in different countries. The implementation 
of guidelines is critical, however is not mandatory, and the veterinarians should adopt these 
to help control the spread of resistant bacteria. To understand if the veterinarians are 
following the guidelines implemented it is necessary to document if the actual prescriptions 
are according to the recommendations (Regula, Torriani, Gassner, Stucki & Müntener, 
2009). 
Antimicrobial use in animals can be monitored via national data on import or sales of 
antimicrobials, via pharmacies. National sales data are used most often, because they are 
relatively easy to obtain. However the indication for the treatment is not included in these 
data and its considered critical to understand if the antimicrobials are used prudently (Regula 






antimicrobials since these agents are sold directly from distributors to veterinary practices. In 
companion animals, cephalosporins and β-lactams represented the majority of all 
antimicrobials used. Many of the criteria stated in recommendations for prudent usage of 
antimicrobials could not be evaluated with the data available in this study and therefore only 
analysed the compliance of veterinarians to the prudent use of antimicrobials (Regula et al., 
2009). 
Antimicrobial agents licensed for human use are also used frequently in companion animals 
(in application of the 'Cascade') (Arts. 10 & 11 of Directive 2001/82/EC of the European 
Parliament and of the Council). Such data is included in the sales data for human 
antimicrobial agents (EMA, 2013). The cascade is a legal flexibility providing a rational 
balance between the legislative requirement for veterinarians to prescribe and use 
authorized veterinary medicines where they are available, and the need for professional 
freedom to prescribe other medicines where they are not.  It is intended to increase the 
range of medicines available for veterinary use particularly when welfare of the animal 
patient could be compromised otherwise (British Small Animal Veterinary Association 
[BSAVA], 2013). According to the cascade, the veterinarian may treat the animal(s) in order 
to avoid unacceptable suffering, in accordance with the following: a veterinary medicine 
authorized from another animal species or for a different condition within the same species. If 
that medicine does not exist, use either a medicine approved for human medicine, or a 
veterinary medicine authorized from another Member State of the EU. In case that there is 
no such medicine, a medicine prepared extemporaneously can be used (Decreto-lei n. º 
148/2008, alterado pelo Decreto-lei 314/2009, artigo 78 [Ministério da Agricultura, do 
Desenvolvimento Rural e das Pescas, 2008]. In this sense, the prescribing cascade 
promotes the responsible antimicrobial use, allowing the veterinarian to use clinical 
judgement to prescribe a drug if no veterinary authorised medicine exists (BSAVA, 2013).
  
In Canada, Weese (2006) performed a retrospective study on prescription for dogs and cats 
at a veterinarian teaching hospital in Ontario, reviewing 10 years of prescribing data (1995-
2004). Overall, 21.152 antimicrobial prescriptions were written for dogs and cats. Extent of 
antimicrobial prescriptions was considered lower than in previous studies performed in 
Canada. The use of first-generation cephalosporins, fluoroquinolones, penicillins and 
trimethoprim-sulphonamides decreased over time; while the use of metronidazole increased 
Factors such as increased awareness regarding consequences of overuse antimicrobials as 
a consequence of the guidelines introduced may have had an important impact. In this study 
the underlying disease for which antimicrobials were prescribed was not investigated, 








2.7. Mechanisms of antimicrobial resistance: Vertical and Horizontal gene transfer 
Several mechanisms are responsible for antibacterial resistance. Bacteria can be innately 
resistant to a specific class of antimicrobial, and all descendants from these bacteria are also 
resistant, named vertical transfer of resistance (Woodford & Ellington, 2007; Bennett, 2008). 
When mutation occurs two scenarios may happen. In one hand the bacteria might only 
reduce the susceptibility to a specific antimicrobial agent to allow the survival until new 
resistant genes are acquired. In the other hand, in some rare cases a single mutation can be 
enough to confer high level resistance (e.g. high-level rifampicin resistance in S. aureus or 
high-level fluoroquinolone resistance in Campylobacter jejuni (Tenover, 2006). Antibiotic 
resistance genes are a major problem and several studies have focused on this issue trying 
to understand what is happening in the core of the bacteria for these to become increasingly 
resistant. It became clear that the mutation could not be the only cause. Further studies were 
required and the attention is now focused on the role of transferable genetic material from 
other resistant organisms (e.g. acquired resistance). This is termed horizontal gene transfer 
and may occur between strains of the same species or between different bacterial species or 
genera (Tenover, 2006). Horizontal transfer can be defined as a process in which DNA 
bacterial is transferred from one cell to other and stay stably incorporated in the other cell 
genome, without cell division ( 
Figure 6) (Carattoli, 2003). 
The DNA can be transferred from one cell to other by three methods: transformation, 
transduction and conjugation, and in these processes new gene (s) from other bacteria are 
acquired. The conjugation process includes plasmids and conjugative transposons which are 
able to transfer genetic material from one cell to other involving replication. To accomplish 
this, the donor bacteria extend an elongated structure named pilus that connects with the 
recipient bacteria. It is necessary that the donor cell and recipient are in direct contact for the 
success of this method. The other elements involved in the conjugation are resistance 
transposons, gene cassettes and inserted sequences (IS) which can transfer genetic 
material within the same cell (e.g. from chromosome to plasmid) by recombination process 
(Bennett, 2008). Transposons are small, mobile DNA elements which include insertion 
sequences and have the ability to move intra and inter DNA molecules inside the cell. The 
resistance genes located in plasmids are often placed in transposons which contain the 
transposase function to facilitate the transposon to recombine into the chromosome or 
plasmid. The importance of transposons in the increase of antibiotic resistance relies on the 
fact that most of them encode resistance to tetracycline or minocycline alone (Rice, 1998; 
Carattoli, 2003; Seiffert et al., 2013). Some transposons are conjugative while others require 






Plasmids, especially conjugative plasmids are genetic mobile elements that move bacterial 
genes from one cell to other. In general, they are autonomous from the host, replication 
process independent, and do not need any set of core genes to start replication, but may 
carry genes that from an evolutionary perspective can be useful for their survival. Plasmids 
are circular, double stranded DNA. A resistant plasmid is defined as a plasmid that carries 
one or more antibiotic resistant genes (Bennett, 2008). According to Salvador Luria, plasmids 
are “among the most fundamental advances in the whole history of bacteriological science” 
(Luria, 1947).  
Integrons can be localised whether in the chromosome or in plasmids. These elements can 
incorporate single genes and they contain an integrase and an attI binding site for the 
integration on cassettes. The cassettes have  an attC repeated sequence in the flanks and 
enables to go to be integrated at the attI site, excised and undergo horizontal gene transfer 
(Seiffert et al., 2013). Integrons are an important vector since they can carry up to eight 
resistant gene cassettes (Naas, Mikami, Imai, Poirel & Nordmann, 2001). Other aspect is 
that any gene can be assimilated in an integron gene cassette which represents an 
advantage for the bacteria (Rowe-Magnus & Mazel, 2002). Four classes of integrons have 
been described. Class 1 and class 2 are the most prevalent among bacteria such as E. coli 
and Salmonella. These integrons are disseminated in companion animals and food-
producing animals. As these integrons are similar to those found in human commensal and 
pathogens it is possible to establish the hypothesis of lateral transfer between humans and 
animals (Stokes & Gillings, 2011).  
Acquisition resistant genes in Enterobacteriaceae is mainly due to plasmids, but some 
studies have pointed out the significance of the ICEs (integrative and conjugative elements) 
as a factor contributing to the dissemination of resistance genes (Mata et al., 2011). ICEs are 
mobile genetic elements found in the chromosome of both gram-positive and gram-negative 
bacteria and can move from the chromosome of one cell to other by meanings of excision, 
and transferred by conjugation (Wozniak & Waldor, 2010). 
During transduction, the DNA transfer through bacteria from the same species is mediated 
by bacteriophages (bacterial viruses), but it is limited to large and double stranded phages 
(50-100kb). Within the bacteria, the bacteriophages can remain inactive as prophages or 
become virulent and start replication which results in maturation of the virus particles and can 
pack his own DNA or acquire it from the host (Frost, Leplae, Summers & Toussaint, 2005). 
In transformation, the bacteria acquires and incorporates DNA segments which are in the 
environment and were released by bacteria after cell lysis (Tenover, 2006). This process was 
the first mechanism of prokaryotic HGT to be discovered (Frost et al., 2005).  
It is not easy to measure the importance of HGT because there is a weak knowledge of the 






is that only a limit number of species are able to be transformable. This process is mainly 
used to monitor the transfer of antibiotic resistant genes (Rizzi et al., 2008). 
As a consequence of these resistance mechanisms, the bacteria can adapt easily to the 
introduction of new bacterial genes and become resistant (Carattoli, 2003). 
 


















2.8. Resistance to β-lactams 
Over the past 60 years, due to the use of β-lactam antibiotics, the production of β-lactamases 
enzymes among gram-negative organisms has increased, especially in Enterobacteriaceae  
(Livermore & Woodford, 2006). The introduction of third generation cephalosporins started 
with cefotaxime 30 years ago and it improved the antimicrobial chemotherapy in humans and 
veterinary medicine. Undoubtedly, as a consequence of the selective pressure exerted by 
these new cephalosporins, resistance in enterobacterial species emerged a few years later 
(Pfeifer, Cullik & Witte, 2010). Bacteria became resistant through one of the three primary 
mechanisms of resistance. The first mechanism and also the most common is the production 
of β-lactamase enzymes that hydrolyse or modify the antibiotic before reaching his target site 
(Figure 7). The β- lactamase breaks a bond in the β-lactam ring to disable the molecule, so 
the bacteria remain resistance to any β-lactam antibiotic. The second mechanism is 
alteration of the antibiotic target site, and these mutant PBPs have low affinity towards β-












lactam antibiotics; the last mechanism is the alteration of permeability or forced efflux that 
inhibits the antibiotic to reach the target (Poole, 2004; Wilke et al., 2005).  
With the increase of β-lactamase producing Enterobacteriaceae in the past 20 years new β-
lactam antibiotics have been developed specifically to fight against the hydrolytic action of β-
lactamases (Medeiros, 1997). The first detection of ESBLs from an animal was reported in 
1988 in Japan isolated in an E. coli from a laboratory dog (Matsumoto, Ikeda, Kamimura, 
Yokota & Mine, 1988). Since then, numerous reports have been made of ESBL producing 
bacteria across Europe, and it is a major problem worldwide (Carattoli et al., 2008). 
To date, more than 1000 β-lactamases have been reported as mentioned 
in http://www.lahey.org/studies/webt.htm. 
 
Figure 7 - Resistance to β-lactam antibiotics: (A). In the gram-negative cell β-lactam antibiotics action 
(B); modification of the targets of the drugs, (C);  the PBPs alterations in porin proteins, (D);  


















The main mechanism of acquired resistance to extended-spectrum cephalosporins in 
Enterobacteriaceae is the production of plasmid-mediated extended-spectrum β-lactamases 
(ESBLs) and/or plasmid-mediated AmpC β-lactamases, and E. coli is one of the major 
producers (Tamang et al., 2012). The ESBLs have been isolated from a wide variety of 
Enterobacteriaceae (Bradford, 2001).  
The ESBLs are defined as a β-lactamases capable of hydrolysing penicillins broad, extended 






group 2 be). The AmpC type β-lactamases which are also commonly isolated from extended-
spectrum cephalosporin-resistant gram-negative bacteria are different from ESBL because 
they are not inhibited by clavulanic acid or other β-lactamase inhibitor. AmpC β-lactamases 
are typically encoded in the chromosome or in plasmids from many gram-negative bacteria 
(Bush, Jacoby & Medeiros, 1995). The β-lactamases are located in the periplasmatic space 
in gram-negative bacteria, whereas in gram-positive are mostly extracellular (Bush, 2010). 
The rapid dissemination of isolates producing ESBLs is considered a major concern due to 
the fact that these plasmids frequently carry genes encoding resistance to other drug classes 
as fluoroquinolones, aminoglycosides, sulfa-derivatives and trimethoprim (Pitout & Laupland, 
2008; Hawkey & Jones, 2009). 
 
2.8.1. Genetics of β-lactamase: inducible or constitutive  
The enzymes encoded in the chromosome can be inducible or have constitutive expression. 
Inducible means that the enzyme is expressed in the presence of a substance (an inducer), 
and constitutive expression means that a gene is transcripted continuously (Mayer, 2010). In 
Enterobacteriaceae, AmpC enzymes encoded in the chromosome are usually inducible  
(Jacoby, 2009; Bush, 2010;). In Table 3 are listed the AmpC β-lactamases producing 
organisms inducible by β-lactam antibiotics such as cefoxitin but poorly induced by the third 
and fourth generations cephalosporins (Jones, 1998; Hanson, 2003). The induction of AmpC 
gene includes the gene products AmpR, AmpD, and AmpG (Hanson & Sanders, 1999). 
The increase of β-lactam resistance in Enterobacteriaceae is a consequence of AmpC 
expression gene which encodes a cephalosporinase very common in E. coli and E. cloacae, 
but with different mechanism patterns (Honoré, Nicolas & Cole, 1986). In E. coli the 
expression of AmpC gene is regulated by a weak promoter and a transcriptional attenuator, 
producing a small amount of enzyme and bacteria are susceptible to ampicillin (Olsson, 
Bergström, Lindberg & Normark, 1983). But the wild strain can undertake some alterations 
and hyper-produces AmpC gene by mutation in a promotor-operator region determining the 
rate of transcription from the structural gene AmpC (Bergström & Normark, 1979). Molecular 
studies evidenced that some strains might have more than one copy of the AmpC gene 
(Nelson & Elisha, 1999). In this case these strains are resistant to practically all β-lactams, 
with the exception of carbapenems (Garau, 1994). 
 
Table 3 - Enterobacteriaceae producing inducible AmpC β-lactamases (adapted from (Jones, 1998) 
Genus  Species  
Citrobacter Freundii 










2.8.2. Transferable resistance 
The dissemination of β-lactamases is due to their location within plasmids and transposons 
which facilitate the transference of resistant genes among bacteria (Bradford, 2001). In this 
sense bacteria gains advantage over antibiotic use, by introducing AmpC enzymes from the 
chromosome into plasmids (Jacoby, 1994). There are several reports in humans, cattle and 
dogs described (Winokur et al., 2000; Sanchez et al., 2002). 
 
2.9. Most important β-lactamases 
In Enterobacteriaceae, the major mechanism of β-lactam resistance is the production of β-
lactamases (Majiduddin, Materon & Palzkill, 2002). This resistance mechanism is often 
associated with mobile genetic elements such as insertion elements, transposons and 
integrons, and is highly selected by the selective pressure caused by the use of β-lactam 
antibiotics (Massova & Mobashery, 1998).  
Since early 1970s different classifications based on phenotype, gene or amino acid protein 
sequences and function have been described (Ambler, 1980; Bush et al., 1995). 
Classification of β-lactamases can be done according to the functional properties (Bush-
Jacoby-Medeiros scheme) defined by the substrate and inhibitor profile (Table 4). There are 
four main groups and multiple subgroups in this system. This classification scheme is of 
much more immediate relevance to the physician or microbiologist in a diagnostic laboratory 
because it considers β-lactamase inhibitors and β-lactam substrates that are clinically 
relevant (Paterson & Bonomo, 2005). Group 1 includes cephalosporinases that are not well 
inhibited by clavulanic acid; group 2 refers to penicillinases, cephalosporinases, and broad-
spectrum β-lactamases that are generally inhibited by active site-directed β-lactamase 
inhibitors; The last group, group 3 includes the metallo β-lactamases (MBL) that hydrolyse 
penicillins, cephalosporins, and carbapenems and that are poorly inhibited by almost all β-
lactams (Bush et al., 1995). In contrast, the Ambler classification scheme divides the β- 
lactamases into 4 classes (A, B, C and D) upon their amino acid sequence and not 
phenotypic characteristics (Figure 8). Class A, C, and D all have a serine at their active site, 
while class B are metallo enzymes that require at least one active site zinc ion to facilitate β- 























2.9.1. TEM ESBLs type 
According to Amber classification, the class A β-lactamases is the most common group and 
consists of TEM, SHV and CTX-M β-lactamases enzymes (Bush et al., 1995). Most ESBLs 
are derivatives of TEM or SHV enzymes and there are over 200 TEM types β-lactamases 
described, as reported in http://www.lahey.org/studies/webt.htm. 
Both TEM and SHV-type ESBLs are often found in E. coli and K. pneumonia, however, 
they have also been found in Proteus spp., Providencia spp., and other genera of 
Enterobacteriaceae (Bradford, 2001). 
The first plasmid-mediated β-lactamase in gram-negative bacteria, TEM-1, was described in 
the early 1960s from a patient in Athens named Temoneira (hence the designation TEM) and 
it is actually the most common β-lactamase encountered in gram-negative bacteria 
(Bradford, 2001; Kaur & Aggarwal, 2013). TEM-1 can be found in many different species of 
the family Enterobacteriaceae, such as, Pseudomonas aeruginosa, Haemophilus influenzae, 
and Neisseria gonorrhoeae due to the fact that is plasmid and transposon mediated 
(Bradford, 2001). Enterobacteriaceae express frequently plasmid encoded broad-spectrum-
β-lactamases such as TEM-1, TEM-2 which confers resistance to amino-penicillins and first 
generation penicillins, but not to third or fourth generation cephalosporins and are inhibited 
by clavulanic acid. The TEM-3 type ESBL derivate from TEM-1 and TEM-2 (Chaibi, Sirot, 
Paul & Labia, 1999; Bradford, 2001; Paterson & Bonomo, 2005). TEM-2 is referred as the 
first enzyme derivate from TEM-1 and it only has one single amino acid substitution. Both 
TEM-2 and TEM-3 have the same hydrolytic profile of TEM-1 (Barthélémy, Peduzzi & Labia 
1985). The first TEM-type β-lactamase that displayed the ESBL phenotype was TEM-3 
reported primarily in 1989 (Bradford, 2001). 
Although the inhibitor-resistant β-lactamases are not ESBLs, they are often discussed with 


















Figure 8 - Current Ambler classification scheme (adapted from Hall & Barlow, 2005; 






enzymes were named first IRT for inhibitor-resistant TEM β-lactamase; however, all have 
subsequently been renamed with numerical TEM designations (Bradford, 2001). 
 
2.9.2. SHV – Type ESBLs 
The first report was discovered from a Klebsiella ozaenae isolate in Germany as a 
chromosomally encoded β-lactamase. The name SHV designates a contraction of sulphydryl 
variable. Subsequent work demonstrated that SHV-1 is identical to the PIT-2 enzyme which 
was described in 1972, encoded by a transposon and found on plasmids of different 
incompatibility types (Heritage, Gascoyne-binzi & Hawkey, 1999). The SHV-type ESBLs may 
be more frequently found in clinical isolates than any other type of ESBLs (Paterson & 
Bonomo, 2005). The first report of SHV enzyme had a narrow spectrum, with activity against 
penicillin, capable of hydrolyse cefotaxime and ceftazidime. Some mutations have occurred 
in the active site of the enzyme which led to other SHV enzymes. These derivate either have 
an extended-spectrum activity towards third generation cephalosporin or are resistant to β-
lactamase inhibitors (Knothe, Shah, Krcmery, Antal & Mitsuhashi, 1983; Heritage et al., 
1999) . The use of third generation cephalosporins can be responsible for the increase and 
dissemination of organisms harbouring SHV-2 (Paterson & Bonomo, 2005). 
SHV- type β-lactamases which are most commonly isolated from K. pneumonia are often 
encoded on large transferable plasmids, reported worldwide and more than 120 types have 
been described (http://www.lahey.org/Studies) (Du Bois, Marriott & Ajnyes, 1995; Bradford, 
2001). 
 
2.9.3. CTX - Type ESBLs 
In the past decade, CTX enzymes have become the most prevalent extended-spectrum β-
lactamases worldwide in healthcare and in community settings. They also have been 
described in farm animals, pets, products from food chain and sewage (Cantón & Coque, 
2006).  This family of ESBLs enzymes were first described in the late 1980’s. The name CTX 
reflects the potent hydrolytic activity of these β-lactamases to cefotaxime. The M in the CTX-
M refers to the city of origin, Munich (Paterson & Bonomo, 2005). These enzymes are 
defined by their capacity to cause resistance to cefotaxime and susceptibility to ceftazidime 
(Pitout, 2008). A notable exception to this is CTX-M-15, the most common CTX-M variant 
which can also cause resistance to ceftazidime in addition to cefotaxime. The CTX-M family 
is a heterogeneous group which had rapidly spread over the last decade and have become 
the most prevalent ESBL (Cantón & Coque, 2006). There are currently more than 100 
different CTX-M enzymes that can be divided into six different subgroups based on their 
amino acid sequences: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, CTX-M-25 and CTX-M-45 







2.9.4. Metallo β-lactamases  
The class B or metallo β-lactamases inactivate the β-lactam antibiotic cleaving the amide 
bond; hydrolyse all β-lactams antibiotics except monobactams. In addition, these enzymes 
have an efficient activity against carbapenems and are not susceptible to β-lactam inhibitors 
(Bebrone, 2007). The first enzyme identified was found in an opportunist environment 
bacteria of Bacillus cereus in 1966, and it was considered clinically unimportant, because the 
metallo β-lactamases genes were intrinsic and chromosome born (Nordmann et al., 2012). 
The metallo β-lactamase resistant genes are located in the chromosome mainly but can be 
also detected in plasmids and integrons (Bebrone, 2007). The plasmid confers the possibility 
of horizontal transfer among pathogenic and/or opportunistic bacteria leading to a serious 
clinical problem (González, Martín, Costello, Tierney & Vila, 2007). The increasing reports of 
MBL led to subsequent studies to evaluate and group them into three subclasses B1, B2 and 
B3 on the basis of their sequence alignments. The group B1 and B3 structurally can bind up 
to two Zinc ions and are capable to hydrolyse most β-lactam antibiotics including penicillins, 
cephalosporins and carbapenems while group B2 only has one zinc ion and is very active 
against carbapenems (González et al., 2007).  
The most important carbapenemases are categorized as three types of enzymes: (i) the KPC 
(K. pneumoniae carbapenemases) type enzymes (ii) the VIM (Verona integron encoded 
metallo β-lactamase), IMP (for “active on imipenem”), and NDM (New Delhi metallo-β-
lactamase) metallo-β-lactamases; and (iii) the OXA-48 type enzymes. The most common 
types found in Enterobacteriaceae are IMP and VIM groups (Queenan & Bush, 2007). The 
IMP metallo β- lactamase was first reported in 1991 in Japan from a Serratia Marsecens. 
These have been progressively disseminating since then to other countries  and into various 
Enterobacteriaceae genus (Serratia marcescens, Klebsiella pneumoniae, Citrobacter 
freundii), Pseudomonas aeruginosa, and other non-fastidious gram-negative non-fermenters 
(Nordmann et al., 2012). 
 
2.9.5. AmpC β-lactamases  
AmpC β-lactamases were the first enzyme described to destroy penicillin and was reported 
in E. coli. The structural gene for the production of the β-lactamase was named blaAmpC 
and the sequence of the gene from E. coli was described in 1981. In Amber classification the 
AmpC enzymes are classified as class C whereas according to Bush are incorporated in 
group 1 based on the functional classification scheme (Bush & Jacoby, 2010). The molecular 
masses of typical AmpC enzymes vary from 34 to 40 kDa, the isoelectric points of ˃ 8.0 and 
are generally located in the bacterial periplasm. AmpC enzymes are active against penicillin, 






cephalosporins (cefepime and cefpirome); hydrolyse cephamycins, like cefoxitin and 
cefotetan, and monobactams. In opposition to ESBLs, AmpC enzymes are poorly inhibited 
by clavulanic acid, sulbactam, and tazobactam, and not at all by Ethylenediaminetetraacetic 
acid (EDTA) (Jacoby, 2009). 
Since the 1970s, the AmpC β-lactamases have been a target of study (Hanson, 2003). The 
AmpC β-lactamases were encoded mainly in the chromosome in various gram-negative 
bacteria e.g. as Enterobacter spp., Citrobacter spp., Serratia spp., P. aeruginosa, and Hafnei 
alvei (Medeiros, 1997). In many Enterobacteriaceae, AmpC expression is low but inducible in 
response to β-lactam usage (Jacoby, 2009). The induction of AmpC β-lactamases is 
controlled by the activity of three proteins: AmpG, AmpD, and AmpR. Usually in a wild type 
strain, AmpC production is expressed at low levels, but when mutation occurs in the AmpD 
and AmpR results in AmpC overexpression or constitutive hyper production and increases 
the β-lactam MICs in organisms with an inducible AmpC (Schmidtke & Hanson, 2006). The 
mechanism most associated with constitutive overproduction of AmpC is due to amino 
acides substitution in the AmpD (Hanson & Sanders, 1999). The hyper production of AmpC 
β-lactamases results in resistance to most β-lactam antibiotics with the exception of 
cefepime, cefpirome, and the carbapenems (Thomson & Moland, 2000). The amount of 
enzyme that is inherited depends on the species on their regulation mechanism. In E. coli the 
production of this enzyme is in the chromosome, usually repressed and at low levels, 
meaning that AmpC is non-inducible (Jacoby, 2009). However if mutations in the promoter 
region occurs there is a hyper production of the enzyme with levels of resistance to ampicillin 
and cephalosporins (Jacoby, 2009). Another important pathogen Salmonella spp. does not 
carry this type of enzyme inherently, but in recent years genes encoding CMY enzymes have 
been described on plasmids (Arlet et al., 2006).  Also Proteus spp. and K. pneumoniae 
normally do not harbour chromosomal blaAmpC genes (Drawz & Bonomo, 2010). Class C 
AmpC β-lactamases include CMY-2, ACT-1, and DHA-1, which are usually encoded 
by bla genes located on the bacterial chromosome (Drawz & Bonomo, 2010). 
In Enterobacteriaceae the genes encoding AmpC were mobilized from the chromosome to 
plasmids and now have spread horizontally between different species of Enterobacteriaceae 
and are becoming more prevalent (Alvarez, Tran, Chow & Jacoby, 2004). The mobilization of 
AmpC genes into plasmid is due to genetic elements as the insertion sequence 
ISEcp1 ,which is associated with many CMY alleles including CMY-2 (Haldorsen et al., 
2008).The plasmid location of this enzyme is usual responsible to encode resistant to other 
antimicrobials class, as fluoroquinolones, aminoglycosides, sulphonamides and trimethoprim, 
as well as genes for other β-lactamases (Alvarez et al., 2004). As a consequence, treatment 







Plasmid-mediated AmpC β-lactamases were reported first in 1988 and derived from older, 
broad-spectrum β-lactamases (e.g. TEM-1, TEM-2,SHV-1), which have an extended 
substrate profile, similar to the chromosomally determined AmpC β-lactamases that permits 
hydrolysis of all cephalosporins, penicillins, and aztreonam  (Thomson, 2001). Susceptibility 
to cefepime, cefpirome, and carbapenems is little, if at all, affected (Jacoby, 2009). The 
exception is that ACC-1 does not confers resistance to cephamycins and is actually cefoxitin 
inhibited (Bauernfeind, Schneider, Jungwirth, Sahly & Ullmann, 1999). 
Plasmid-mediated AmpC β-lactamases have been reported around the world in both animal, 
human and nonnosocomial isolates, having been most easily detected in those 
Enterobacteria not expected to produce AmpC β-lactamases (Jacoby, 2009). These 
enzymes exhibit high similarity with chromosomally determined AmpC β-lactamases, and 
thus probably represents the progenitors for the plasmid encoded enzymes (Jacoby, 2009). 
Plasmid-mediated AmpC β-lactamase (pAmpC) includes several families which exhibit little 
differences between them, and are grouped into nine groups, including 90 CMY alleles, 13 
variants of ACT and 10 of FOX, 8 variants of DHA and MOX, 5 of MIR and ACC, and CFE-1 
and LAT-1 (http://www.lahey.org/Studies/). 
One of the concerns about plasmid-mediated resistance to β-lactams is that often encode 
additional resistance to other antimicrobial class, as aminoglycosides, 
chloramphenicol, fluoroquinolones, sulphonamides, tetracyclines, and trimethoprim (Alvarez 
et al., 2004). The most common plasmid-mediated AmpC β-lactamase worldwide is CMY-2, 
and to date more than 100 alleles have been reported (http://www.lahey.org/Studies/ ). In 
annex 2, the main characteristics of blaCMY-2 gene are illustrated. CMY-2 gene is not inducible 
while other genes for ACT-1, DHA-1, DHA-2, and CMY-13 are linked to AmpR and are 
inducible (Jacoby, 2009). CMY gene has two different origins and six varieties (CMY-1, 8, 9, 
10, 11, and 19), are related to chromosomally determined AmpC enzymes in Aeromonas 
spp., while the others (including CMY-2) are related to AmpC β-lactamases of Citrobacter 
freundii (Barlow & Hall, 2002). 
The plasmid encoded enzyme can be a hard task to identify since phenotypic identification is 
difficult and it can be misidentified as extended-spectrum β-lactamases (Hanson, 2003). 
There are no guidelines to detect plasmid encoded AmpC mediated resistance in gram-
negative organisms. When an organism shows resistance to cefoxitin can indicate the 
possibility of AmpC producer but can also indicate reduce outer membrane permeability  
(Thomson, 2001; Jacoby, 2009). To detect all ESBLs and AmpC-type β-lactamases 
according to EFSA, testing cefotaxime and the use of epidemiological cut-off values should 
be sufficient. It is important to distinguish cefoxitin AmpC producers from cefoxitin resistant 
non-AmpC producers, because therapy options are different. In the first case carbapenems 






recommended for the latter (Coudron, Hanson & Climo, 2003). A multiplex PCR for the 
detection of plasmid encoded ampC genes was developed by Pérez-Pérez & Hanson (2002), 
a rapid and useful test to distinguish between AmpC producers and non-producers (Pérez-
Pérez & Hanson, 2002). 
The concern among researchers is based on the fact that these enzymes can be plasmid-
mediated in gram-negative, and have been found not only in humans but also in livestock 
and companion animals. These findings address the question about surveillance in order to 









Table 4 - β-lactamases classification scheme (adapted from Bush & Jacoby, 2010). 
a CA - Clavulanic acid; TZB – Tazobactam. 
b EDTA - Ethylenediaminetetraacetic acid.
Classification by Jacoby- Medeiros Inhibited by 
Group Molecular class Substract Characteristics CA/TZB a EDTAb 
1 C Cephalosporins Greater hydrolysis of cephalosporins than benzylpenicillin; hydrolyzes 
cephamycins 
NO NO 
1e C Cephalosporins Increased hydrolysis of ceftazidime and often other oxyimino-β-lactams NO NO 
2a A Penicillins Greater hydrolysis of bezylpenicillin than cephalosporins YES NO 
2b A Penicillins, early cephalosporins Similar hydrolysis of benzylpenicillin and cephalosporins YES NO 
2be A Extended-spectrum 
cephalosporins, monobactams 
Increased hydrolysis of oxyimino-β-lactams (cefotaxime, ceftazidime, 
ceftriaxone, cefepime, aztreonam) 
YES NO 
2br A Penicillins Resistance to clauvulanic acid, sulbactam, and tazobactam NO NO 
2bre A Extended-spectrum 
cephalosporins, monobactams 
Increased hydrolysis of oxyimino-β-lactams combined with resistance to 
clavulanic acid, sulbactam, and tazobactam 
NO NO 
2c A Carbenicillin Increased hydrolysis of carbenicillin YES NO 
2ce D Carbenicillin, cefepime Increased hydrolysis of carbenicillin, cefepime, and cefpirome YES NO 
2d D Cloaxillin Increased hydrolysis of cloaxcillin or oxacillin Variable NO 
2de D Extended-spectrum 
cephalosporins 
Hydrolyses cloaxcillin or oxacillin and oxyimino-β-lactams Variable NO 
2df D Carbapenems Hydrolyses cloaxicillin or oxacillin and carbapenems Variable NO 
2e A Extended-spectrum 
cephalosporins 
Hydrolyzes cephalosporins. Inhibited by clavulanic acid but not aztreonam YES NO 
2f A Carbapenems Increased hydrolysis of carbapenems, oxyimino-β-lactams, cephamycins Variable NO 
3a B (B1) Carbapenems Broad-spectrum hydrolysis including carbapenems but not monobactams NO YES 




















3. Use of antimicrobials in companion animals 
 
3.1. Aim of this study 
In several countries, the monitoring programs are focused on food-producing animals. In 
general most countries have some data about the antimicrobial use in animals but it’s not 
very accurate in companion animals. According to the directive EU 2004/28/EC it is 
mandatory that all member countries compile detailed antimicrobial data. Some countries 
have this task easier since the prescription antibiotics are surrendered by pharmacies and 
are included in their annual reports (DANMAP, 2012; SWEDRES-SVARM, 2012). In Portugal 
for instance, the pattern of prescription is unknown and there is no national monitoring 
program to follow the antimicrobial usage in companion animals. The lack of data in this area 
led to the creation of this survey in order to gather information, quantify and characterise the 
patterns of antimicrobial usage in companion animals. The rational use of antimicrobials in 
small animals should become second nature to veterinarians. Since most veterinary 
practices do not perform bacterial culture and susceptibility testing before antibiotic 
prescription, with this project another aim is to raise the awareness of veterinarians for the 
importance of performing bacterial culture and testing antimicrobial susceptibility, which will 




The specific aims of the study were: 
 
(i) To analyse the patterns of antimicrobial prescription from veterinarians in small 
animal practice, in Portugal; 
(ii) To determine the use and/or possible misuse of antimicrobials in companion animals 





















3.2. Material and methods 
3.2.1. Validation of the survey 
Initially a pilot study was performed. The questionnaire was tested on 30 people (including 
veterinarians and pet owners) randomly selected, in order to validate and identify potential 
problems. The pilot study was successful and no changes were made to questionnaire. 
The survey was sent by the OMV to all veterinarians with an active subscription, to a total of 
4800 veterinarians. 
 
3.2.2. Data collection 
The survey was available in an online platform, named SurveyMonkey® accessible at 
www.surveymonkey.com. The veterinarians were asked to answer the survey, were informed 
of the purpose of this study and were kindly requested to leave their email address in case 
they would like to know the results of this study. This survey was online since the 19th 
November 2012 until 1th March 2013.  
The questionnaire was composed of three sections (see annex 3) the first section refers to 
socio-demographic data from the respondents (age, gender, year of practice, specialization). 
The second section included the antimicrobial prescribing practices (sources of information 
for antimicrobials, importance of clinical signs, microbiological culture and weight when 
prescribing antimicrobials). In the last section of the questionnaire, the clinicians were 
requested to choose according to the underlying disease which antimicrobial would be 
prescribed to assess appropriateness of antimicrobial selection. 
 
3.2.3. Statistical analysis 









3.3.1. Response rate 
A total of 183 surveys (n=183) were started. Eighty one of the answered questionnaires were 
not completed, leaving 102 completed questionnaires and a useable response rate of 3%. 
 
3.3.2. Questionnaire based analysis 
The majority of veterinarians who responded to the questionnaires were females (n= 130; 
72%), while man accounted for 28% (n= 30), as illustrated in Figure 9. Most of the 
veterinarians worked in a Veterinary Clinic (n= 91; 51%), 22% (n= 39) worked in a Veterinary 
Practice and 17% (n= 31) worked in a Veterinary Hospital (data not shown). 
Regarding their qualifications, most of the veterinarians (n= 114; 64%) did not hold any post 
graduate qualifications while 37% (n= 66) hold post-graduate qualifications but no details 

















Overall 87% (n= 140) of respondents referred the dog as the most common animal species 
presented for consultation, 11% (n= 17) referred to cats and 2% (n= 3) referred to other 
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When analysing antimicrobial usage patterns, as illustrated in Figure 11, 2% (n= 3) always 
prescribed antimicrobials on a daily basis, 43% (n= 68) prescribed antimicrobials frequently, 


















































Figure 10 - Distribution of animal species in veterinary practices. Others 
included rabbits, goats and dogs and cats in the same proportion. 
Figure 11 - Frequency of antimicrobial prescription in veterinary practices.  
a
 Rarely - One to 5 prescriptions per week; Sometimes – five to ten times per 








For dogs and cats the preferred antimicrobial formulations prescribed by veterinarians were 
oral preparations with 74% (n= 119) and 58% (n= 92) respectively. Injectable antimicrobial 
accounted for 25% (n= 40), 41% (n= 66) and topic solutions were only applied by 
veterinarians in 1% of animals (both species). The preference of antimicrobial preparation for 
dogs and cats is presented in Figure 12 and Figure 13 respectively. 
   
Figure 13 - Preference antimicrobial 
administration route for cats. 
 
Antimicrobials are prescribed on a normal routine day. To understand the patterns of 
antimicrobial prescription, it was asked some questions to the veterinarians about their 
prescription habits, as illustrated in Figure 14. The question: How often do you prescribe 
antimicrobials empirically without a confirmed diagnosis? The answers were: 1% (n= 1) 
always used antimicrobials with no diagnosis made; 30% (n= 48) very often prescribed 
before the diagnosis is made; 45% (n= 72) sometimes; 23% (n= 37) performed some tests 



















































































Figure 12 - Preference antimicrobial administration 
route for dogs. 
Figure 14 - Frequency of antimicrobial prescription without a diagnosis confirmed. 
 
a 
Rarely - One to 5 prescriptions per week; Sometimes – five to ten times per week; 






In the following of the previous question: How often do you use culture and antimicrobial 
susceptibility tests before prescribing antimicrobials? 
The respondents were consistent with the previous answer. One percent (n= 2) always 
performed tests; 6% (n= 10) very often used culture and susceptibility tests, 37% (n= 59) 
sometimes 48% (n= 77) rarely performed any test and 8% (n= 12) never used any kind of 
















Eighty-eight per cent (n= 140) always weighed animals, 8% (n= 12) weighed animals 
frequently, 1% (n= 2) weighed animals sometimes, 3% (n= 4) weighed animals rarely, and 





























































Frequency of weighing animals a 
Figure 15 - Frequency of susceptibility testing performed before prescribing 
antimicrobials. 
a 
Rarely - One to 5 prescriptions per week; Sometimes – five to 
ten times per week; very often – more than 10 times per week; Always – a 
prescription for each appointment. 
 
Figure 16 - Frequency of weighing animals for which antimicrobials are 
prescribed. 
a 
Rarely - One to 5 prescriptions per week; Sometimes – five 






When asked about the importance of factors when deciding to treat an animal with 
antimicrobials, spectrum of action (n= 143; 89%) was found to be the most important factor, 


























The most commonly antimicrobial prescribed for dogs using a scale of 1-5 (with 1 being the 
most frequent, and 5 being the least frequent) was amoxicillin-clavulanate (n= 153), followed 
by enrofloxacin (n= 132) and metronidazole (n= 126) (Figure 18 and Figure 19).  For cats 
amoxicillin-clavulanate (n= 151) was also the most important antimicrobial prescribed, 































Factors for antimicrobial selection a 
Figure 17 - Main factors considered when selecting an antimicrobial for 
treatment. a Owner Characteristics (economics, compliance); Animal 
characteristics and behaviour; Mode of action; 
Pharmacokinetics/pharmacodynamics; Spectrum of action; Route of 
administration; Antimicrobial cultures susceptibility testing; Acute or chronic 


















































































Figure 18 – Most common antimicrobial recommended for dogs. 






3.3.3. Appropriateness of antimicrobial use 
In the last section of the survey (5 questions) the veterinarians were asked to choose among 
the different antimicrobials, which you would prescribe for each condition. In each question 
the more common clinical conditions in dogs and cats were included. The total respondents 
in this section of the survey was equal in all five questions (n= 102). Results were analysed 
by animal species as follows. In annex 4, tables with percentage values for each figure are 
presented. 
 
For skin/soft tissue disorders, a total of possible prescriptions were (n= 965). Overall, the 
most frequent antimicrobial chosen was amoxicillin-clavulanate (38%), followed by 
enrofloxacin (18%) cephalexin (15%), and metronidazole (7%) (data not shown). 
In dogs, for all conditions presented, amoxicillin-clavulanate was the drug of choice, followed 
by cephalexin in pyoderma and deep pyoderma, while in bacterial otitis was enrofloxacin 
(23%). For abscess conditions metronidazole was the second choice of veterinarians (18%) 
(Figure 20). In cats, amoxicillin-clavulanate was also the antimicrobial of choice followed by 







































For urinary tract infections (including complicated UTI) enrofloxacin was the most prescribed 
antimicrobial in cats and dogs followed by amoxicillin-clavulanate and cephalexin (Figure 22 
and Figure 23). In pyometra condition in dogs, amoxicillin-clavulanante (34%) was the choice 
of veterinarians. In cats, FLUTD (a cat specific condition – explained in the discussion of the 































































In gastrointestinal conditions, in dogs and cats, metronidazole was the antimicrobial of choice 
followed by amoxicillin-clavulanate and enrofloxacin. For chronic gastroenteritis in both dogs 
















































































For the respiratory tract disorders presented, amoxicillin-clavulanate was the antimicrobial of 
choice, followed by enrofloxacin, in pneumonia and pyothorax (29%; 25% respectively), in 
dogs. Doxycycline was the first line preferred by veterinarians for tracheobronchitis (Figure 
26). In cats, for feline upper respiratory tract disease and feline respiratory complex, 
amoxicillin-clavulanate (40%; 32%) was the therapeutic option by veterinarians, followed by 
doxycycline (21% and 28%). Exception was made for pneumonia and pyothorax for which 











































































































































































































Figure 26 - Respiratory tract conditions in dogs disorders and the antimicrobials chosen by 







Clindamycin was the antimicrobial of choice for osteomyelitis in dogs and cats representing 
25% and 22% of veterinary choices respectively; cephalexin was the second option (23%), 
followed by amoxicillin-clavulanate (14%). In this question we also asked which drugs were 
prescribed before surgery. Most of the veterinarians selected amoxicillin-clavulanate (42% in 
dogs and cats), and 19% referred that no therapeutic was used as prophylaxis in both dogs 






































































Figure 27 - Respiratory tract infections in cats and the antimicrobials chosen by veterinarians 
 (n =102). 
Figure 28 - Orthopedic diseases – prophylaxis in dogs and the antimicrobials chosen by  






































Figure 29 - Orthopedic diseases – prophylaxis in cats and the antimicrobials chosen by  







The increasing public awareness of antimicrobial resistance has led to a network surveillance 
regarding antimicrobials usage in both veterinary and human medicine. This survey 
represents a good method for collecting data about antimicrobial prescription patterns in 
companion animals in Portugal. The response rate in our study was low (3%). However it is 
considered satisfactory as a pilot study performed in Portugal. This percentage is not 
consistent with a previous study conducted in the UK where an useable response rate of 
51% was confirmed (Hughes et al., 2012). According to Chauvin (2002), when a reminder is 
sent the response rate increases (Chauvin, Beloeil, Orand, Sanders & Madec, 2002). In this 
study no reminder was sent out because the availability of e-mail addresses was a limiting 
factor.  
The questionnaire about the patterns of antimicrobial prescribing provides an overall view. It 
is however essential to have a validated questionnaire with a reasonable number of 
questions, so the response rate may be reasonable and statically representative of the 
sample. In our study the third part (prescription-based condition antimicrobial usage) was 
considered for some veterinarians as being long and detailed. This opinion might have 
influenced the response rate in this part of the questionnaire, since those 81 veterinarians did 
not complete this last part of the survey. In further studies these issues will be addressed in 
order to increase the response rate to relevant sections. 
 
The most common animal species attending at the veterinary practice was the dog (87%) 
whereas the cat represented only 11% according to respondents in this study.  
 
Regarding the prescription of antimicrobials on a normal day at work, according to our study, 
43% per cent prescribed very often (more than 10 prescriptions a day) and 51% prescribed 
sometimes (from 5 to 10 prescriptions a day). These results are in agreement with other 
studies where is reported that antimicrobials agents were  used very often in small animal 
practice (Grave, Bangen, Engelstad & Soli, 1992).  
 
When asked about the importance of criteria when choosing an antimicrobial, the spectrum 
of action of an antimicrobial was the most important parameter for the majority of 
veterinarians (89%), followed by route of administration (73%) and owner characteristics 
(62%). Interestingly the organism involved in the infection was only ranked in the 6th in the 
level of relevance (52%). Our results are not in agreement with previous studies. According 
to Hughes (2012) the main factor in which a veterinarian chooses an antimicrobial was the 
clinical signs presented, followed by bacterial culture and ease of administration (Hughes et 






Many veterinary organizations have published guidelines for prudent or judicious 
antimicrobial use (CVMA, 2000; Morley et al., 2005; AVMA, 2006) underlying the importance 
of performing bacterial culture and susceptibility to confirm diagnosis and to guide while in 
therapy. However, in this study most veterinarians referred to not performing routinely 
cultures or susceptibility testing before antimicrobial prescribing. Only 1% of the veterinarians 
referred that they always performed cultures and susceptibility testing before prescribing an 
antimicrobial. Forty eight per cent answered that rarely performed these tests, which is 
consistent with other similar studies (Thomson, Rantala, Viita-Aho, Vainio & Kaartinen, 
2009). According to antimicrobial prudent use it is recommended to know which organism is 
causing the infection to make a correct decision about the antimicrobial to use and to avoid 
treatment failure (BSAVA, 2013) . Besides that, performing cultures would potentially reduce 
the number of inappropriate antibiotic prescriptions (Stegemann et al., 2006). 
 
In our study most veterinarians (88%) always weighed animals before prescribing 
antimicrobials. Weighing animals before prescribing an antimicrobial is in agreement with 
recommendations on antimicrobial use. As a consequence, the veterinary prescribes the 
correct dose of antimicrobial. Some previous studies in vitro have pointed out a relation 
between exposing bacteria to a sub-inhibitory concentration of antimicrobials and the rise of 
antimicrobial resistance which leads to a less efficacy in the treatment (Choe, Bouhaouala, 
Brook, Elliott & Knudson, 2000; Gillespie, Basu, Dickens, O’Sullivan & McHugh, 2005). 
 
In our study the main antimicrobial prescribed for dogs and cats were potentiated amoxicillin 
and enrofloxacin. The high prevalence of broad spectrum β-lactams is consistent with data 
previously reported in Finland (Rantala, Hölsö, Lillas, Huovinen & Kaartinen, 2004; Thomson 
et al., 2009). In Australia, amoxicillin-clavulanate and first generation cephalosporins were 
considered also the most commonly used drugs in dogs (Watson, 2001). The large use of 
enrofloxacin in dogs and cats is a matter of concern since fluoroquinolones are considered 
critically important in human medicine. It is therefore important that their use is restricted to 
complicated clinical situations in order to maintain their effectiveness (Rantala et al., 2004). 
In a study conducted in the United Kingdom, the use of enrofloxacin accounted for 3-4% in 
dogs and 4-5% in cats  Usage of broad spectrum antimicrobials such potentiated amoxicillin 
and enrofloxacin may be also an indicator of uncertainty or inaccurate diagnosis of the 
underlying condition (Mateus, Brodbelt, Barber & Stärk, 2011). In Portugal, enrofloxacin is 
authorized for use in dogs and cats. It is indicated for using in several conditions (e.g. 
respiratory tract infections, urinary tract infections and skin infections) (Apifarma, 2011). 
Current guidelines of the British Small Animal Veterinary Association recommends whenever 






is based on the fact that a broad spectrum  antimicrobial should have less impact on the 
normal microbiota (Hughes et al., 2012). However, in some clinical conditions such as 
pyoderma, pyothorax and periodontitis broad spectrum antimicrobials are recommended 
(Guardabassi et al., 2008; Maddison, 2009). The use of broad spectrum antimicrobials may 
also indicate the lack of tests performed in order to identify the organism responsible for the 
infection. The use of fluoroquinolones, a broad spectrum antimicrobial class may reflect the 
awareness of veterinarians about the β-lactam resistant bacteria or a perception that 
fluoroquinolones are more suitable in certain clinical scenarios(Hughes et al., 2012). 
 
In dogs and cats interestingly the less prescribed antimicrobials were clindamycin, 
pradofloxacin and cefovecin. Usage of cefovecin was low probably due to the cost involved 
for treating medium to large dogs. In cats, usage was also very low. According to Mateus 
(2011) the use of cefovecin in cats was high, which had not been previously reported 
(Thomson et al., 2009; Mateus et al., 2011). 
 
In the third part of this survey, the veterinarians were asked to choose an antimicrobial agent 
for the most common clinical conditions in dogs and cats. Most veterinarians preferred to use  
clavulanate-amoxicillin for the treatment of all skin infections. This antimicrobial is now 
recommended for the treatment of pyoderma (Vanni et al., 2009). It is also interesting that 
the use of trimethoprim-sulphonamides, lincosamides and tetracyclines was low. These 
findings were in agreement with similar studies carried out in Finland and Australia (Watson, 
2001; Rantala et al., 2004). The low percentage of trimethoprim-sulphonamides in our study 
is also consistent with other studies where the emergence of resistance in staphylococci is a 
limiting factor for trimethoprim-sulphonamides usage (Rantala et al., 2004). There are also 
several side effects that have been reported (e.g. thrombocytopenia, leukopenia, crystalluria 
and fever) (Swedish Veterinary Association [SVA] (2009).This can also be a reason for the 
low preference by veterinarians.  In the case of lincosamides it is now recommended that 
they should not be used for  canine pyoderma treatment (Rantala et al., 2004).  
 
In our study the prevalence use of enrofloxacin in dogs and cats for urinary tract infections 
when compared with previous studies is in disagreement, since urinary tract conditions are 
mainly treated with β-lactams (Murphy et al., 2012). In cats for instance are seldom caused 
by bacteria but more due to underlying disease causes such as urethra plugs and urinary 
calculi (Thomson et al., 2009). Fluoroquinolones should not be used to treat an 
uncomplicated UTI unless the culture and susceptibility testing have showed that others 






The term feline lower urinary tract disease (FLUTD) was first used in 1980 to describe 
variable combinations of straining, hematuria, pollakiuria (frequent passage of small amounts 
of urine), and periuria (urinations in inappropriate locations (Westropp, 2008). Interestingly, in 
our study, 43% did not choose any therapeutic for FLUTD, which is according to the 
guidelines. However, in many occasions it was treated with enrofloxacin (31%) and 
amoxicillin-clavulanate (34%) consistent with previous reports (Watson, 2001). Since no 
specific test is used to diagnose FLUTD, the disease remains a diagnosis of exclusion. The 
frequent use of antimicrobials is concerning since bacteria is not the underlying cause for this 
condition, it is mainly stress related (Watson, 2001). After the treatment with antimicrobial, 
some relief is noted, but might be caused by treatment of the underlying cause (Thomson et 
al., 2009). The implementation of MEMO – “Multimodal Environmental Modifications and the 
increased intake of water are the main recommendations (SVA, 2009). 
For pyelonephritis, enrofloxacin and amoxicillin-clavulanate were the preference choice of 
the veterinarians. According to the Swedish Veterinary Association (SVA) culture and 
antimicrobial susceptibility tests should be performed before antimicrobial treatment (SVA, 
2009). However, renal function remains at risk while pending for the results, empirical 
treatment should be started as soon as possible (SvHKS, 2013).  
 
Our findings refer metronidazole as the antimicrobial of choice for most of the gastro- 
intestinal clinical conditions, followed by amoxicillin-clavulanate and enrofloxacin. These 
findings are in agreement with a study conducted by German (2010), where the most 
common  used antimicrobial were amoxicillin-clavulanate and metronidazole (German, 
Halladay & Noble, 2010).  Also, according to Watson and Maddison (2001), most Australian 
veterinarians use antibiotics in dogs with unspecific gastroenteritis (Watson, 2001). The use 
of antimicrobials for gastro-intestinal clinical conditions is not normally considered according 
to some studies (Rantala et al., 2004; Watson, 2001), because the antimicrobials may 
change the microflora and exert some selective pressure for the emergence of resistant 
strains of bacteria (Hughes et al., 2012). 
 
In addition, amoxicillin-clavulanate was the antimicrobial of choice to treat all respiratory 
clinical conditions, followed by doxicycline and/or enrofloxacin.  These data is consistent with 
previous studies (Murphy et al., 2012). The use of cefovenin in our study was low (1%-4% in 
both dogs and cats) in all clinical conditions presented. These results are consistent with 
specific recommendations because this antimicrobial is not approved for respiratory tract 
infections. However, they are in disagreement with others in which cefovecin was the second 
most commonly prescribed antimicrobial in cats (Murphy et al., 2012).  Cefovecin is a third 






drug for staphylococci infection when owner compliance and or administration can be a 
problem (Hughes et al., 2012). The use of doxyclicline in our study in most conditions 
presented is the second choice, except for pneumonia (both in dogs and cats), where 
amoxicillin-clavulanate was the main choice followed by enrofloxacin.  
Doxycycline is a recommended antimicrobial for tick borne infections and canine 
tracheitis/bronchitis, commonly known as “kennel cough” (SVA, 2009; SvHKS, 2013). 
 
When considering the use of antimicrobials for prophylaxis in many surgical procedures, 
participating veterinarians referred amoxicillin-clavulanate as the most common antimicrobial 
chosen (48% in both dogs and cats). Our results are in agreement  with the literature where 
the use of amoxicillin-clavulanate is considered to be more effective and less likely to cause 
antimicrobial resistance (Rantala et al., 2004). According to the American College of 
Veterinary Internal Medicine´s Consensus Statement on Antimicrobial Drug Use notes that 
prophylactic administration of antibiotics is justified in some cases (Morley et al., 2005). In 
orthopaedic clinical conditions, also amoxicillin-clavulanate was the preference (54% and 
52% in dogs and cats respectively), followed by cephalexin with 39% and 36% respectively. 
In osteomyelitis the antimicrobial choice was clindamycin (44% and 37% in dogs and cats) 
which is consistent with previous studies (Watson, 2001) 
 
Our findings suggested that the β-lactam antimicrobials class was the most commonly 
prescribed and these results are similar to those of previous studies investigating 
antimicrobial use in veterinary practices (Watson, 2001). This fact may be due to the ease 
administration, few side effects and low cost.  However, the use of this drug as a first choice 
in many clinical conditions without culture and susceptibility testing is not appropriate (AVMA, 
2007). 
 
Enrofloxacin was the second antibiotic choice in this study. The frequency of antimicrobial 
prescription events with fluoroquinolones reported in this study is considered higher than 
previous reports (Rantala et al., 2004; Weese, 2006; Mateus et al., 2011). Enrofloxacin is a 
wide-spectrum, bactericidal antibiotic used for treating mixed infections. The low percentage 
of cultures performed in this study indicates a probable inappropriate use of enrofloxacin in 
uncomplicated urinary tract infections Their use should be based on current guidelines 
specially since enrofloxacin resistance is being associated with multidrug resistance (Weese, 
2006; Shea, Annie, Mccarthy & Lindenmayer, 2012). In order to decrease the development 
of antimicrobial resistance, it is recommended to use narrow spectrum antibiotics whenever 
possible, so perhaps in some situations an alternative choice of antibiotic would have been 






In this study neomicin (n= 13) was chosen for colitis and enteritis in dog and cats; 
nitrofurantoin (n= 5) for complicated urinary tract infections in cats (n= 1), pyelonephritis in 
dogs (n= 2), prostatitis in dogs (n= 1) and FLUTD (n= 1); and phosphomycin for treating 
uncomplicated and complicated urinary tract infection in dogs (n= 2). 
 
As mentioned previously, cats and dogs were exposed to some critically important 
antimicrobials in veterinary and human medicine. In this study, the low response of 
veterinarians to answer the third section of this survey was a limiting factor for understanding 
the patterns of antimicrobial prescription. The results presented cannot determine whether 
the usage of antimicrobials in dogs and cats is adequate. Therefore further studies and a 
continuous surveillance system for antimicrobial usage with more detailed information is 
necessary to evaluate the risk of antimicrobial resistance in companion animals. To analyse 
and conclude about the usage of antimicrobials in companion animals, complete and 
accurate data is needed addressing the animal species, such as, age, weight, clinical 
condition. Other aspects as antimicrobial agent, frequency, route of administration, duration 
of the treatment and previous antimicrobials prescribed are crucial to understand the patterns 
of prescription and evaluate the risk of antimicrobial resistance, and assess if guidelines are 
being followed by veterinarians. In our study it was not possible to gather all this important 
data since the compliance was not high in this survey. This reflects the importance of 
























4. Characterization of cephamycin resistant in Enterobacteriaceae 
 
4.1. Aim of this study 
The resistance to β-lactams producing Enterobacteriaceae is a public health issue. The 
genes encoding β-lactamases may be present in transferable plasmids or in the   
chromosome. Plasmids play an important role in the horizontal transfer and there is a 
potential zoonotic risk of dissemination of these resistant genes between humans and 
animals. The information about the plasmid-mediated AmpC β-lactamases among 
Enterobacteriaceae in companion animals was limited. The objective of this study was to 
assess the presence of pAmpC genes among Enterobactereaceae isolates collected from 
companion animals and human clinical isolates. And, subsequently characterize the positive 
isolates by using molecular methods for plasmid characterization. Identification of pAmpC in 
Enterobacteriaceae isolated from companion animals and humans may be an evidence of 




The specific aims of the study were: 
 
(iii) To assess the prevalence of pAmpC β-lactamases producing Enterobacteriaceae in 
companion animals from Portugal and Denmark; 
(iv) To characterize pAmpC β-lactamases producing isolates and compare them, in order 







4.2. Material and Methods 
4.2.1. Bacterial strains/isolates 
In this study, isolates were collected from Portugal (animal and human origin isolates) and 
Denmark (only animal origin isolates) (Table 5). The isolates chosen to be included in this 
study were selected based on their resistance profile. The Portuguese isolates inclusion 
criteria were: cefoxitin, amoxicillin-clavulanate resistant and cefepime susceptible. A total of 
61 (n= 61) isolates from animal origin were included (22 E. coli isolates, 18 Enterobacter spp. 
isolates, 10 Proteus spp. isolates, 9 Klebsiella spp. isolates, 1 Serratia marsecens isolate 
and 1 Citrobacter freundi isolate. The isolates includes 41 from urine (67%) 5 from wounds 
(8%), 5 from skin swab (8%), 4 from ear (7%), 3 from swab (5%), 1 from abdominal fluid 
(2%) and 1 from prostate liquid and puncture disc (2%). These isolates belonged to the 
collection in the Laboratory of Antibiotic Resistance from the Faculty of Veterinary Medicine, 
and were collected from January 2000 to November 2012. Regarding humans isolates, 11 
(n= 11) E. coli isolates belonged to the collection of TechnoPhage, from the Molecular 
Medicine Institute, Lisbon. The isolates were human community-acquired urinary tract 
infections from the Lisbon area. Sixteen  (n= 16) E. coli isolates from Denmark, from dogs 
and cats, belonged to the Veterinary Hospital in Copenhagen, collected from 2010 to 
October 2012, were included in this study.  The inclusion criteria for the Danish isolates 
were: cefoxitin and amoxicillin-clavulanate resistant. The 16 E. coli isolates included 4 from 
urine (25%), 7 from wounds (44%), 3 were unknown (19%), 1 from ear (6%), 1 from biopsy 
(6%). All isolates were stored at -80°C. In total, this study started with 88 Enterobacteriaceae 
isolates and this data was compiled on Excel file for further analysis.  
 
Table 5 - Origin from the isolates included in this study. 
 Animal isolates (n= 77) Human isolates (n= 11) 
Total (n= 88)  Portugal (n= 61) Denmark (n= 16) Portugal (n= 11) 
Organism Dog Cat Dog Cat Human 
E. coli 18 4 15 1 11 49 
Proteus spp. 8 2 - - - 10 
Enterobacter spp. 11 7 - - - 18 
Klebsiella spp. 7 2 - - - 9 
Serratia spp.  1 - - - - 1 
Citrobacter spp. 1 - - - - 1 








4.2.2. Antimicrobial susceptibility testing 
4.2.2.1. The disc diffusion method 
Antimicrobial susceptibility testing was performed using the standard disc diffusion method 
on Mueller-Hinton Agar (MH2, Biomérieux) with an inoculum equal to 0,5 McFarland turbidity, 
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines for animals. 
The plates were incubated at 37ºC for approximately 18 hours. The following discs (Oxoid) 
were used: Amoxicillin-clavulanic acid (30µg); Cefoxitin (30µg), Cefotaxime (30µg), 
Imipenem (30µg), Ciprofloxacin (5µg), Tetracycline (30µg), Gentamicin (10µg), and 
Trimethoprim-sulfamethoxazole (25µg) (Table 6).  
The detection of ESBL producing Enterobacteriaceae was accomplished by the double disc 
synergy between amoxicillin-clavulanic acid and an expanded-spectrum cephalosporin, for 
example cefotaxime and/or ceftazidime. The test is considered positive if after the incubation 
period the inhibition zone between the discs is enhanced (Rupp & Fey, 2003). 
The results were registered by measuring the zone of inhibition diameter and interpreted 
according to the CLSI breakpoints for animals (CLSI, 2008) and according to the human 
CLSI breakpoints (CLSI, 2012) when the data was unavailable. 
 
Table 6 - Diffusion disc method. Susceptibility criteria according to the Clinical Laboratory Standards 
Institute. 
a 
Inhibition zone diameters were interpreted according to: 
(b)
 CLSI M31-A3 and 
(c)
 CLSI M100-S22;  
S - Susceptible; I - Intermedius; R - Resistant; 
 
 
4.2.2.2. Broth micro dilution method 
The minimum Inhibitory Concentrations (MIC) of cefoxitin (512 μg/ml), was determined 
according to CLSI guidelines by broth microdilution for ampC β-lactamase producers. 
Escherichia coli ATCC25922 strain was used as control strain for determination of MIC 
values. The minimum inhibitory concentration (MIC) is defined as the lowest concentration of 
antibiotic that completely inhibits growth (Yan et al., 2002). The determination of the MIC is 
considered a gold standard  to assess the antibiotic potency, despite its limitations, it should 
Antibiotic class Antibiotic Abbreviation Disc Diameter a 
   (µg) S I R 
Penicillin associations Amoxicillin/clavulanic acid b AMC 20/10 ≥18 14-17 ≤13 
Cephalosporins 
Cefoxitin c FOX 30 ≥22 15-21 ≤14 
Cefotaxime c CTX 30 ≥23 15-22 ≤14 
Fluoroquinolones Ciprofloxacin c CIP 5 ≥17 14-16 ≤13 
Aminoglycosides Gentamicin b CN 10 ≥16 13-15 ≤12 
Tetracycline Tetracycline b TE 30 ≥19 15-18 ≤14 
Potentiated sulphonamides Trimethoprim-sulphamethazolb SXT 25 ≥16 11-15 ≤10 






be performed to validate the results obtained by other methods (MacGowan & Wise, 2001). 
The results were analysed according to the principle of the MIC, and bacterial growth was 
easily detected, mostly as a pellet on the bottom of the well. 
VetMIC Stördjur® (National Veterinary Institute, Uppsala, Sweden) for small animals was 
also performed according to the manufacturer´s instructions, to confirm the results obtained 
by the MIC for cefoxitin. The antibiotics tested were: ampicillin (2 - 8 µg/mL), cephalotin (4 - 
16 µg/mL), cefotaxime (0,03 - 12 µg/mL), amoxicillin-clavulanate (2/1 - 8/4 µg/mL), 
nitrofurantoin (4 - 16 µg/mL), gentamicin (0,25 - 1 µg/mL), trimethoprim-sulphonamide 
(0,5/9,5 µg/mL), tetracycline (0,5 - 2 µg/mL) and enrofloxacin (0,008 - 0,03 µg/mL). The 
results were interpreted according to M31-A3 (CLSI, 2008), and M100-S22 (CLSI, 2012) ( 
Table 7). 
 
Table 7 - VetMIC® interpretative criteria for Enterobacteriaceae. 
 
    
4.2.3. Detection and sequencing of β-lactamase genes 
4.2.3.1. Total DNA isolation 
The protocol to extract DNA was based on the boiling lysis method. Briefly, in a sterile 
eppendorf®, a loop (disposable - white; 1μl) with 3-4 isolated colony (plated on blood agar 
and incubated for 18 hours) was dissolved in 100 µl MiliQ water and this suspension was 
boiled for 10 minutes. Lysate prepares were clarified by centrifugation at 1400 x g, 4ºC 
during 15 minutes. Then the clarified supernatant was transferred into a 1.5ml eppendorf® 




M31-A3 (CLSI, 2008) M100-S22 (CLSI, 2012) 
MIC (µg/mL) MIC (µg/mL) 
S I R S I R 
Ampicillin ≤8 16 ≥32 - - - 
Cephalotin ≤8 16 ≥32 - - - 
Cefotaxime - - - ≤1 2 ≥4 
Amoxicillin/clavulanic acid ≤8/4 16/8 ≥32/16 - - - 
Nitrofurantoin - - - ≤32 64 ≥128 
Gentamicin ≤2 4 ≥8 - - - 
Trimethoprim-sulphonamide ≤2/38 - ≥4/76 - - - 
Tetracycline ≤4 8 ≥16 - - - 






4.2.3.2. pAmpC gene detection  
All isolates that exhibited resistance to cefoxitin, after growth from the stored cultures, were 
screened for the presence of ampC genes by the multiplex polymerase chain reaction (PCR) 
described by Pérez-Pérez & Hanson (2002) E. coli J53 pMG144 carrying blaDHA-1, Proteus 
mirabilis 1089/07 carrying blaCMY-2, E. coli J53 pMG251 carrying blaACT-1, E. coli J53 PMG 252 
carrying blaFOX, Klebsiella Nu2936 carrying blaMOX and Klebsiella 96D carrying blaMIR were 
used as positive control strains.. Isolates positive for the AmpC phylogenetic group CIT were 
subjected to a specific PCR targeting the entire blaCMY gene. The multiplex PCR was 
performed with modifications from the described by Pérez & Hanson (2002) (Pérez-Pérez & 
Hanson, 2002) with a final volume of 50 µl. The primers used for amplification are listed in 
Table 8. Each reaction contained 1.74 μl of MiliQ water, 3 μM of each of the following primers 
(10 μM) MOXMF, MOXMR, CITMF, CITMR, DHAMF, DHAMR; 2.5 µM primers ACCMF, 
ACCMR, EBCMF, EBCMR, FOXMF. FOXMR, 10 μl of 5x PCR buffer without MgCl2; 3 μl  of 
Mgcl2 (25µM), 0.5 deoxyribonucleotide triphosphates (dNTPs) (25 mM), 0,26 μl DMSO 5%, 
and 0.5 μl of NZYTech Taq (NZYTech, Lisbon, Portugal) The template DNA was added to 48 
µl of the master mixture. Thermo cycling conditions included an initial denaturation step at 
94˚ C for 3 minutes, followed by 25 cycles of DNA denaturation at 94°C for 30s, primer 
annealing at 65°C for 30s, primer extension at 72°C for 1 min, and the final step, a single 
final extension at 72°C for 7 min was added. 
PCR products were subjected to electrophoresis on 1,5% agarose gel (NZYTech, Lisbon, 
Portugal) with tris-borate-EDTA (TBE) 0.5x or tris-acetate-EDTA (TAE) 1x and stained with 
ethidium bromide 10mg/ml (Invitrogen, CA, EUA), to identify the amplified DNA fragments 
(as referred below in the protocol). Molecular weight of the PCR amplicons was determined 
by comparison with a 100-bp ladder molecular weight standard (Ladder V, 100-1000pb 
NZYTech, Lisbon, Portugal). The bands were visualized by using UV transullimination 
(Thermal Imaging System FTI-500, Amersham Pharmacia Biotech, Piscataway, EUA).  
 
4.2.3.3 Purification and sequencing of DNA 
The PCR products were purified using PCR Product Purification Kit (NZYtech, Lisbon, 
Portugal) according to the manufacturer’s instructions. PCR primers used are listed in Table 
8. 
 
4.2.3.4. Data analysis of DNA sequences 
DNA sequencing was performed by STAB VIDA – DNA sequencing (Oeiras, Portugal). The 
nucleotide sequences were analysed and compared with known sequences using the basic 
local alignment search tool (BLAST) which is available on the homepage of the National 






Table 8 - PCR and sequencing primers used in this study. 
 
 
4.2.3.5. Detection of Extended spectrum β-lactamases using PCR multiplex 
AmpC β-lactamase producers were also screened by PCR multiplex to detect the presence 
of TEM, SHV and OXA-1 enzymes, as described by Pomba (2006). CTX-M enzymes were 
screened by a simplex PCR adapted from Edelstein, Pimkin, Palagin, Edelstein & 
Stratchounski ( 2003); Pomba  (2006). 
 
4.2.3.6. Plasmid analysis 
Plasmid DNA was extracted from all strains producing β-lactamases. The protocol used was 
adapted from Bimboim & Doly (1979). The protocol followed was: the strains were grown in 
10 ml of BHIB (Brain Heart Infusion Broth) overnight. A volume of culture (1.5ml) was 
transferred to an eppendorf® tube (0.5-1.5 ml) and was centrifuged (13.000 rpm for 2 
minutes), and the supernatant was discarded. After, 150 µL SET-buffer (saccharose, EDTA 
and trisaminometano-TRIS base) was added and vortex immediately. The tubes were 
centrifuged for 15 seconds. Therefore 350 µl of lysis solution (1% sodium dodecyl sulfate –
SDS; 0,2M sodium hydroxide - NaOH) was added and the tubes were gently inverted 10 
times. The tubes were maintained for 5 minutes at room temperature and afterwards 250 µl 
of KAc (potassium acetate) solution was added. The tubes were maintained at 0°C for 60 
Primers 
 









 F-GCT GCT CAA GGA GCA CAG GAT 
    R-CAC ATT GAC ATA GGT GTG GTG C 
PCR 520  
CIT 
 
F-TGG CCA GAA CTG ACA GGC AAA 
R-TTT CTC CTG AAC GTG GCT GGC 
PCR 462  
DHA 
 
    F- AAC TTT CAC AGG TGT GCT GGG T 






 F- AAC AGC CTC AGC AGC CGG TTA 
R- TTC GCC GCA ATC ATC CCT AGC 
PCR 346  
EBC 
 
 F- TCG GTA AAG CCG ATG TTG CGG 
 R- CTT CCA CTG CGG CTG CCA GTT 
PCR 302  
FOX 
 
   F- AAC ATG GGG TAT CAG GGA GATG 
 R- CAA AGC GCG TAA CCG GAT TGG 
PCR 190  
CMY 
 
    F- ATG ATG AAA AAA TCG TTA TGC 






    F- TACGATACGGGAGGGCTTAC 




    F- TCAGCGAAAAACACCTTG 




    F- TATCTACAGCAGCGCCAGTG 














minutes to allow moist of the protein, high molecular weight RNA and chromosomal DNA to 
precipitate. Centrifugations were done for 15 minutes to achieve a clear supernatant. The 
supernatant was removed and transferred to a new eppendorf® containing 500 µl of 
isopropanol and the tubes were inverted 10 times. The next step included harvesting the 
DNA by centrifugation for 15 minutes and discarding the supernatant. The pellet refers to the 
pDNA which was dissolved in MiliQ water. 
 
4.2.3.7. Transfer of resistance 
pDNA was transformed into electrocompetent Genehog® E. coli (Invitrogen, Taastrup, 
Denmark). The protocol followed was: 1µl of pDNA was added to Genehog® E. coli and 
mixed gently with a pipette. Further, was placed in an electroporation cuvette (electrode gap 
0.2 cm) and transformed (pulse conditions: 2.5 Kv, 25 µF, 200 Ω). Immediately 1 ml of Brain 
Heart Infusion Broth (BHIB, Oxoid A/S, Greve, Denmark) pre-warmed at 37ºC was added to 
the cuvette to wash the cells and transferred to a new eppendorf® tube. This solution was 
incubated for 1 hour at 37ºC on a heating block to allow expression of the antibiotic resistant 
gene. Then, 100 µl of this solution was distributed on selective plates and non-selective 
plates to ensure well-spaced colonies for counting and picking. The plates and the recovery 
solution were incubated overnight at 37ºC. Transformants were selected on Brain Heart 
Infusion agar (BHIA, Oxoid A/S, Greve, Denmark) plates containing 2 µg/mL cefotaxime. 
Selected colonies were analysed by PCR to confirm that the transformants contained the 
blaCMY-2 or the blaDHA-1 gene that was found in the donor strain. 
 
4.2.3.8. Plasmid replicon typing 
Total DNA from transformants were obtained as described previously using a boiling lysis 
method and used as a template in a Polymerase Chain Reaction-based Replicon Typing 
Method (PBRT) using a PBRT-kit (Diatheva, Italy), according to the manufacturer´s 
instructions. In order to identify the more common replicon circulating among 
Enterobacteriacea, a method by Carattoli (2005) was developed The plasmid 
characterization is based on incompatibility (inc) groups (Carattoli et al., 2005a). 
Plasmids that were negative in the PBRT analysis were designated “non-typeable”. The 
primers and protocols for the specific incompatibility groups can be retrieved at 
http://pubmlst.org/plasmid/. The pMLST method is a specific method for plasmid typing 
based on a DNA sequence which recognizes similar plasmids and their detection among 
isolates from different countries. This typing method contributes to gather knowledge about 
the types of plasmids circulating in animals and humans by describing the spread of 






Briefly, the pMLST method involved PCR amplifying  and sequencing genes essential for 
replication and maintenance, which include: pill, a gene within the pil locus involved in pilus 
biogenesis; sogS, a primase involved in discontinuous plasmid DNA replication; ardA, 
encodes a type-I restriction enzyme, repI1, the RNAI antisense regulating system in the IncI1 
replication system and the intragenic trbA- pndC region involved in maintenance and plasmid 
transfer respectively (García-Fernández et al., 2008).  
 
 4.2.3.9. S1 nuclease PFGE  
The DNA fragments larger than 25 kb to be separated, it is mandatory to use pulsed-field gel 
electrophoresis (PFGE), which involves the application of alternating current, from different 
directions (Boultwood, 1994). According to this principle DNA fragments are separated by the 
speed at which they reorient themselves with the changes in current direction (Lai, Birren, 
Clark, Hood & Simon,1989). In order to investigate the presence of plasmids and their size 
PFGE was performed according to CDC PulseNet protocol  (Ribot et al., 2006) and is 
presented below. Both enzymes and buffers used in the restriction enzyme process 
belonged to Thermo Fisher Scientific Inc., USA. A Salmonella serotype Braenderup strain 
(H9812) was used as a reference strain (Hunter et al., 2005). Thiourea (100µM) was added 
to the running buffer. Pictures of PFGE gels were taken by Gel/ChemiDoc system (Bio-Rad 
Laboratories). The following protocols were used: A pure culture of each isolate is grown in 
blood agar plates at 37ºC for 18 hours. Cells were suspended in CSB (3 ml) and adjusted to 
an optical density of 0.83 to 0.87 at 600 nm.  Ten µl of proteinase K solution (20mg/ml) was 
added to optimize cell lysis. Meanwhile the agarose gel solution 1% (SeaKem® Gold 
agarose, FCM Bioproducts) was prepared and a volume of 200 µl melted agarose was 
added. Gel plugs were formed by pipetting 200 μl volumes into plug molds and were allowed 
to solidify at 4°C for 10 minutes. The plugs were transferred to 50 ml tubes containing 5 ml of 
cell lysis buffer (50 mM Tris-HCl, 50 M EDTA, pH 8.0, 1% N- lauroyl sarcosine, 20 mg/ml 
proteinase K). The plugs were removed and placed into a 50 ml screw cap tube and were 
incubated at 54ºC for 2 hours; Plugs were then washed with 10-15 ml TE buffer (10 mM Tris-
HCl, 1 mM EDTA [pH 8.0]) twice and with sterile double distilled preheated water (4 times) 
with agitation at 50º. Plugs were stored in 10 mM Tris-HCl-100 mM EDTA (pH 8.0) at 4°C.  
 
Restriction enzyme digestion 
Before running a PFGE, thin slices of a plug of each isolate to be tested was treated with S1-
nuclease to linearize the plasmids. For Salmonella braenderup (used as a marker) and 
clinical isolates there was a pre-incubation for 15m at 54ºc with the respective buffer and 
water. Then, the solution was discarded and restriction with XBA1 (20U/µl) for S. braenderup 






respectively was accomplished. The solution was removed, plug slices were loaded directly 
into the wells were and the wells were sealed with molten tempered agarose. Meanwhile the 
gel 1% SeaKem® Gold agarose in 10x TBE was prepared and poured on into the tray. It was 
left to solidify for 30 minutes.  Then, the gel was placed in an electrical field device, CHEF-
DR III System® (Bio-Rad Laboratories, CA, USA)   and the pulse time was initial switch time 
6.8s, final switch time 38.4s, total runtime 19 hours; voltage 6.0 V/cm = 200V and angle 120º. 
The gel was stained with 0.0001% (or 1 µg/ml) ethidium bromide for 20 minutes followed by 





























4.3.1. Detection of AmpC β-lactamase-producing  
Antimicrobial resistance phenotype was confirmed for all 88 (n= 88) isolates by the disc 
diffusion method. A total of 62 (70%) isolates examined were resistant to cefoxitin. MICs of 
cefoxitin were performed in isolates positive to multiplex AmpC (n= 21). To confirm the 
results, VetMIC® was performed to these isolates (n= 21) as is illustrated in Table 9. 
 
4.3.2. Molecular Identification of β-lactamases genes 
A multiplex PCR to detect resistance gene were performed subsequently (Erro! A origem 
da referência não foi encontrada.). From the 72 Portuguese isolates analysed 18 (25%) 
isolates were positive to group CIT, and 3 (4%) were positive to DHA gene. A simplex 
multiplex was performed in order to confirm the presence of blaCMY-2 and blaDHA-1 gene. 
Twenty one isolates (n= 21; 29%) were positive for blaCMY-2 and blaDHA-1 gene.  Out of 16 (n= 

















Lane 1 and 14 - GeneRuler DNA Ladder V 100-1000bp. From lane 2 to lane 7 - positive controls. Lane 
2 – E. coli J53 pMG144 carrying blaDHA-1; lane 3 - E. coli J53 pMG251 carrying blaACT-1;; lane 4 - 
E. coli J53 PMG 252 carrying blaFOX;  lane 5 - Proteus mirabilis 1089/07 carrying blaCMY-2;  lane 6 -  
Klebsiella Nu2936 carrying blaMOX; lane 7- Klebsiella 96D carrying blaMIR; lane 8 – 10/2012, lane 9 
– 28/2011, lane 10 – 51/2012, lane 11- 29/2011, lane 12 – 41/2011, and lane 13 – negative control. 
 
 
4.3.3. Transference of resistant genes 
Plasmid transference was performed by electroporation in isolates (n= 32), and it was 
positive in 26 isolates, representing a success rate of 81% (Figure 31). In the remaining 
isolates transformation was not successful, meaning that there was no visible growth in 
selective plates (BHIA+cefotaxime 2µg/ml), despite the growth in non-selective plates. 
72 isolates 
Lisbon region 
 1   2    3   4     5    6   7    8   9    10  11  12 13  14 







Further, transformants were subjected to a simplex PCR to confirm the presence of blaCMY-2 
and blaDHA-1 gene respectively. 
The results demonstrated that the plasmid harbouring the blaCMY-2 gene was transferred 
successfully to the recipient strain Genehog® E. coli as confirmed by the PCR (Figure 32). 
However when performed the simplex PCR for blaDHA-1 gene all isolates were negative. 
Despite repeated attempts the PCR was still negative. The hypothesis suggested is that the 
resistance gene was harboured in the chromosome and not in a plasmid, or in a different 
plasmid. To confirm this hypothesis hybridization with the specific probe would confirm the 
chromosomal location of blaDHA gene. Due to restriction in time this was not done at the time 









































Lane 1 –GeneRuler DNA Ladder Mix 100-10000bp; lane 2 - E. coli positive control; lane 3 - 6933/04; 
lane 4 - 71/2012; lane 5 - 1089/07; lane 6 - 28/2011; lane 7 - 6077/09;  lane 8 - 919/09; lane 9 - 
2038/05; lane10 - 4138/10; lane 11 - 6034/04; lane 12 - 25/2011; lane 13 - 41/2011; lane 14 - 434/00; 
lane 15 - 29/2011; lane 16 - K. penumoniae; lane 17 - 51/2012; lane 18 - negative control. 
Figure 31 - Growth of transformants on selective plates. 
1      2      3      4      5       6      7      8    9   10   11   12     13    14   15   
16    17   18 







Table 9 – Results from resistance profile by disc diffusion, MIC and VetMIC®. 
Strain No. 
Susceptibility test by disc diffusion a MIC VetMIC a 
AMC b CTX c FOX c CIP c CN b TE b SXT b IPM b FOX AMP b KF b CTX c AMC b F b CN b SXT b TE b ENR b 
6933/04 0 18 0 20 28 0 0 18 32 > 8 > 4 > 1 > 16/8 > 32 ≤ 2 > 4/76 > 8 4 
1089/07 0 19 12 12 0 0 0 19 32 > 8 > 4 > 1 > 16/8 > 32 > 16 > 4/76 > 8 > 4 
4138/10 0 11 10 12 30 0 12 21 32 > 8 > 4 > 1 > 16/8 > 32 ≤ 2 > 4/76 > 8 > 4 
74/2012 0 20 9 0 0 0 0 14 16 > 8 > 4 > 1 > 16/8 > 32 16 > 4/76 > 8 4 
6034/04 0 16 11 0 0 0 0 21 32 > 8 > 4 > 1 > 16/8 > 32 2 > 4/76 > 8 4 
28/2011 11 9 0 0 0 0 0 27 128 > 8 > 4 > 1 > 16/8 > 32 > 16 > 4/76 > 8 > 4 
K.pneumoniae 0 0 0 0 0 0 0 25 256 > 8 > 4 1 > 16/8 ≤ 16 > 16 > 4/76 > 8 > 4 
K.oxytoca 10 25 0 0 0 0 0 28 128 > 8 > 4 > 1 > 16/8 > 32 ≤ 2 ≤ 0.5/9.5 > 8 > 4 
414/02 0 12 0 0 0 0 0 28 > 256 > 8 > 4 > 1 > 16/8 > 32 > 16 > 4/76 > 8 > 4 
1975/05 0 11 0 0 0 0 0 28 > 256 > 8 > 4 > 1 > 16/8 > 32 > 16 > 4/76 > 8 > 4 
2038/05 0 15 0 21 22 27 0 28 256 > 8 > 4 > 1 > 16/8 ≤  16 ≤  2 > 4/76 2 2 
859/06 0 12 0 0 20 0 29 21 > 256 > 8 > 4 > 1 > 16/8 ≤  16 ≤  2 ≤  0,5/9,5 > 8 > 4 
434/00 13 15 0 30 0 0 0 31 > 256 > 8 > 4 > 1 > 16/8 32 ≤  2 > 4/76 > 8 0,5 
6346/05 9 12 0 11 10 0 23 25 > 256 > 8 > 4 > 1 > 16/8 16 > 16 0,5/9,5 > 8 > 4 
4919/09 0 18 8 0 0 0 0 24 128 > 8 > 4 > 1 > 16/8 > 32 ≤  2 > 4/76 > 8 > 4 
6077/09 0 11 0 0 19 0 28 22 > 256 > 8 > 4 > 1 > 16/8 ≤  16 > 16 > 4/76 > 8 > 4 
25/2011 0 15 0 0 0 0 0 28 64 > 8 > 4 > 1 > 16/8 32 > 16 > 4/76 > 8 > 4 
29/2011 0 15 0 0 0 0 25 24 64 > 8 > 4 > 1 > 16/8 ≤  16 > 16 > 4/76 > 8 > 4 
41/2011 0 0 0 0 12 0 0 28 64 > 8 > 4 > 1 > 16/8 32 ≤  2 > 4/76 > 8 > 4 
10/2012 10 0 0 0 0 0 28 23 128 > 8 > 4 > 1 > 16/8 ≤  16 > 16 > 4/76 > 8 > 4 
51/2012 12 15 0 0 0 0 0 27 64 > 8 > 4 > 1 > 16/8 32 32 ≤  0,5/9,5 > 8 > 4 
a
 AMC – amoxicillin-clavulanate; CTX – cefotaxime; FOX – cefoxitin; CIP – ciprofloxacin; CN – gentamicin; TE – tetracyclin; SXT – trimethoprim-sulphonamides; 
AMP  Ampicillin; KF - cephalotin; F - nitrofurantoin; ENR – enrofloxacin. 
b  
Criteria according to CLSI , 2008; 
c 






4.3.4. Plasmid Characterization 
The PCR based replicon typing was performed in all transformants (n= 26) (Figure 33). 
Overall, from the Portuguese isolates (n= 21), seventeen (n= 17; 81%) were positive to IncFII 
incompatibility group; one isolate (n= 1; 5%) incorporate the IncA/C plasmid; and one isolate 
(n= 1; 5%) harboured an IncI1 plasmid.  The two remaining isolates were considered non-
typeable by this method. All five isolates from Denmark (n= 5), belonged to IncI1 replicon 
















Left image: Lanes 1 and 19- GeneRuler DNA Ladder Mix 100-10000bp; lane 2- positive controls for 
HIB (570bp), FIB-M (440bp) and FII (258-262bp) replicons; lane 3- 6933/04; lane 4- 1089/07; lane 5-  
4138/10; lane 6- 74/2012; lane 7- 6034/04; lane 8- 28/2011; lane 9- K.pneumoniae; lane 10- 
K.oxytoca; lane 11- 414/02; lane 12- 2038/05; lane 13- 859/06; lane 14- 6346/05; lane 15- 4919/09; 
lane 16- 10/2012; lane 17- 51/2012. The blue narrow refers to a non-typeable plasmid and the pink 
narrow to the IncI1 and IncA/C replicon type. Right image: Lane 1 GeneRuler DNA Ladder Mix 100-
10000bp; lane 2- positive controls for HI1 (534bp), HI2 (327bp) and I1 (142bp) replicons; lane 3-
30029; lane 5- 29969; lane 6- 28463; lane 7- 28464; lane 8- 30104; lane 9- 29870 (negative strain). 
 
Table 10 - PCR based-replicon typing results. 
Origin isolates 
blaCMY-2 gene blaDHA-1 gene 
Total 
repFII repIncI1 repA/C non-typeable repFII 
Animal isolates 
(n=23) 
13 5 1 1 3 23 
Human isolates  
(n=3) 
1 1 - 1 - 3 
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4.3.5. S1 nuclease PFGE  
S1-PFGE was performed in all transformants (n= 26). As it is shown in Figure 34, left image 
there is DNA degradation (smear pattern) in all isolates. To overcome this situation thiourea 
(100µM) was added to the tris-containing buffer (Zhang et al., 2004). In this study the use of 
thiourea solved the problem of DNA degradation. Plasmids from Portuguese isolates 
belonged to three different incompatibility groups: IncFII/F of ca. 78 Kb, one isolate IncA/C of 
ca. 140 Kb; and one IncI1 of ca. 86 Kb. Two isolates: Klebsiella pneumoniae and E. coli 
(human origin) were non-typeable by PBRT method, but in S1-PFGE gel plasmids were 











Middle image: Lanes 1, 8 and 15 - Salmonella enterica serovar Branderup molecular mass marker; 
lane 2- 6933/04; lane 3- 6346/05; lane 4- 74/2012, lane 5- 1089/07, lane 6- 4919/09, lane 7- 4138/10; 
lane 9- 6034/04, lane 10- E. coli; lane 11- K. pneumoniae; lane 12- 28/2011; lane 13- 1975/05; lane 
14- 51/2012. Right image: Lanes 1 and 8 - Salmonella enterica serovar Branderup molecular mass 
marker; lane 2- 30104; lane 3- 28463; lane 4- 28464; lane 5- 29969; lane 6 - 30029. 
 
 
4.3.6. Plasmid analysis 
I1 and FII plasmids were submitted to pMLST as described in the pubmed database. All 
isolates that belonged to IncFII (n= 17) incompatibility group were sequenced and the results 
according to the FAB formula were: F2:A-:B-. Amplicons were compared with known allelic 
variants  and sequence types (ST) assigned using the pMLST database 
(http://pubmlst.org/plasmid) (García-Fernández et al., 2008). Out of 6 (n= 6) Inc1 plasmids, 3 
(n= 3) were classified as ST2 and the remaining three were considered non-typeable by 
pMLST (Table 11). In two out of the three non-typeable a new allele ardA 20 was reported in 
this study for the locus ardA. Antimicrobial susceptibility testing on transformants was done 
to detect co-transference of antimicrobial resistance. In IncFII plasmids the results showed 
additional resistance to other antimicrobials agents such as ciprofloxacin, gentamicin, 
tetracycline’s and sulphametoxazole-trimethoprim; whereas the IncI1 plasmids did not 
transfer any additional resistance besides to β-lactam antimicrobials. 
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Table 11 - Plasmid characterization. 
 Plasmid characterization 
Strain Origin bla gene (s) Replicon typing Plasmid size(Kb) pMLST  Co-transferred resistance
c
 
PT6933/04 Dog CMY-2 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT1089/07 Dog CMY-2 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT4138/10 Dog CMY-2 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT74/2012 Dog CMY-2 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT6034/04 Cat CMY-2 FII 78.2 F2:A-:B- AMC, FOX, CIP,  CN, TE, SXT 
PT28/2011 Dog CMY-2 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PTK. pneumoniae Dog CMY-2 Negative 33.3 - AMC, CTX, FOX 
PTK.oxytoca Dog  DHA-1 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT414/02 Dog DHA-1 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT1975/05 Human CMY-2 Negative 28,8 ; 104-138
a
 - AMC, CTX, FOX 
PT2038/05 Human CMY-2 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT859/06 Human CMY-2 I1 86 ST2 AMC, CTX, FOX 
PT434/00 Dog CMY-2 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT6346/05 Cat CMY-2 A/C 138.9 F2:A-:B- AMC, CTX, FOX 
PT4919/09 Dog CMY-2 FII 78.2 F2:A-:B- AMC,  FOX, CIP, CN, TE, SXT 
PT6077/09 Dog CMY-2 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT25/2011 Dog CMY-2 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT29/2011 Dog CMY-2 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT41/2011 Dog CMY-2 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT10/2012 Dog DHA-1 FII 78.2 F2:A-:B- AMC, CTX, FOX, CIP, CN, TE, SXT 
PT51/2012 Dog CMY-2 FII 78.2 F2:A-:B- AMC FOX, CIP, CN, TE, SXT 




 AMC, CTX, FOX 




 AMC, CTX, FOX 
DK30029 Dog CMY-2 I1 78.2-104
b
 ST2 AMC, CTX, FOX 
DK29969 Dog CMY-2 I1 54.7 NT
d
 AMC, CTX, FOX 
DK30104 Dog CMY-2 I1 78.2-104
b







Two plasmids were detected; 
 
b 
plasmid size between these two values;  
c 
AMC - amoxicillin-clavulanate; CTX - cefotaxime; FOX - cefoxitin; CIP - ciprofloxacin; CN - 
gentamicin; TE - tetracycline; SXT - trimethoprim-sulphonamides; 
 
d






The objective of this study was to assess the presence of pAmpC genes among 
Enterobactereaceae isolates collected from companion animals and human clinical isolates 
and to subsequently characterize positive isolates by using molecular methods for plasmid 
characterization. 
 
From the 49 E. coli isolates the pAmpC genes were detected in 33 E. coli isolates, while in 
Klebsiella spp isolates was detected in 3 of the 9 isolates. In Proteus spp the pAmpC gene 
was detected in 5 of 10 isolates and in 1 out of 18 Enterobacter spp. isolates. E. coli 
produces chromosomal AmpC β-lactamases at low level and may hyper produce due to 
mutations in promoter or attenuator region (Siu, Lu, Chen, Lin & Chang, 2003). E. coli 
isolates which were resistant to cefoxitin but did not carry any gene belonging to the CIT 
group analysed by PCR multiplex, may either hyperproduce cAmpCs or produce a novel 
pAmpC which is not detected by the multiplex PCR (Singtohin et al., 2010) Both K. 
pneumonia and Proteus spp. lacks the cAmpCs (Siu et al., 2003).  
 
In our study a dominance of CMY-2 type plasmid-mediated AmpC (26%) was detected in 
isolates from animal and human origin consistent with worldwide observations (Naseer, 
Haldorsen, Simonsen & Sundsfjord, 2010; Fam et al., 2013;). In a recent study, blaCMY-2 gene 
was detected in one third of the 150 canine and feline E. coli isolates from urinary tract 
infection, suggesting that was the most common β-lactamase (O’Keefe, Hutton, Schifferli & 
Rankin, 2010). According to Carattoli (2005) the increase of Enterobacteriaceae producing 
cephalosporinase detected in dogs and cats is due to the diffuse off-label veterinary use of 
extended spectrum cephalosporins (Carattoli et al., 2005b). However in a study conducted 
by Zhao (2001) revealed that many isolates possessing blaCMY-2 genes were recovered from 
animals that had no history of exposure to cephamycins and extended-spectrum 
cephalosporins (Zhao et al., 2001). Reports refer that AmpC enzyme is less common than 
ESBL among Enterobacteriaceae. However, in a study conducted in a Canadian hospital the 
rates of plasmid AmpC β-lactamases were higher than the rate for extended-spectrum β-








In addition we also observed a low prevalence of blaDHA-1 (3%) gene, and these results are in 
agreement with other studies where this gene was detected in only two isolates from dogs in 
the Republic of Korea (Tamang et al., 2012). The occurrence of  blaDHA-1 has previously been 
described in human clinical E. coli isolates, and is the most prevalent gene in china (Li et al., 
2008).  
 
In the present study the majority of our isolates, blaCMY-2 gene was able to be transferred 
successfully by transformation to a recipient E. coli Genehog® strain. The blaDHA-1 gene 
interestingly did not transfer to recipient strains, despite multiple attempts which indicate that 
this genetic determinant could be located in the chromosome and not in a plasmid. To 
assess this hypothesis southern hybridization could be determined to confirm, however it 
was out of the scope of this study, and time was a limiting factor. 
 
Both blaCMY-2 and blaDHA-1 genes were plasmid encoded. blaCMY-2 (n= 23) gene belonged to 
replicon type IncF (n= 14; 54%), followed by IncI1 (n= 6; 23%) replicon type and one isolate 
(n= 1; 4%) harboured an A/C plasmid. Two isolates (n= 2; 8%) were considered “non-
typeable” by this method. FII plasmid sized 78.2 Kb, IncI1 sized from 54 to 104 Kb, while the 
A/C plasmid sized 138.9 Kb. Our results showed high prevalence of IncFII plasmids (54%) 
and these results are consistent with previous studies since IncFII plasmids are narrow host 
range representing one of the most common plasmid types in clinical relevant 
Enterobacteriaceae (Carattoli, 2009). IncFII plasmids are known by encoding important 
resistant genes, as exemplified by the spread of blaCTX-M-15 genes (Boyd et al., 2004). 
Recently blaNDM-1 gene was reported to be encoded in an IncFII plasmid.  This plasmid type 
spreads efficiently among bacteria which is of great concern (Bonnin, Poirel, Carattoli & 
Nordmann, 2012).  For example in a report this replicon type was reported in E. coli from 
faeces of healthy with no history of antimicrobial use, and also in the faecal flora from healthy 
birds in the USA (Johnson et al., 2007). Overall, IncFII plasmids showed  highest occurrence 
among typed resistant plasmid in human and animal isolates detected in most countries  
(Sherley, Gordon & Collignon, 2003; Johnson et al., 2007). It is possible to assume that the 
detection of the same gene (blaCMY-2) within the same plasmid (IncFII) is responsible for the 
spread and diffusion of this plasmid. In our results, the blaDHA-1 (n= 3; 11%) gene was 
encoded in a 78.2 Kb IncFII plasmid. This findings is in agreement with previous reports 
(Carattoli, 2009).  
I1 incompatibility group was detected in 6 (n= 6; 23%) isolates: one (n= 1) E. coli isolate from 
human origin, and in all 5 (n= 5) isolates from Denmark. In other studies, this plasmid type is 






al., 2010; Dierikx et al., 2012). IncI1 plasmids carrying the blaCMY-2 gene was reported in 
canine E. coli isolates from Italy (Winokur, Vonstein, Hoffman & Uhlenhopp, 2001). In 
another study conducted in Denmark IncI1 plasmids were the most common replicon type 
among dogs (Damborg, Gaustad, Olsen & Guardabassi, 2011). IncI1 plasmid carrying CMY-
2 gene was reported in Norway, as the most common replicon type among humans (Naseer 
et al., 2010). The host range and the reporting in several countries indicates high mobility 
(Winokur et al., 2001). Comparing with our results, the I1 replicon typing was reported in an 
E. coli isolate from human origin, and in this work only three human isolates were 
considered, which represents a limiting factor.  
 
One (n= 1) blaCMY-2 gene was located in an A/C plasmid, and it is consistent with other 
authors. In a study conducted by Johnson (2007) on E. coli isolates from faecal flora of 
healthy animals demonstrated that the repA/C replicon tying was absent, and when 
compared with the results obtained in healthy humans the prevalence was 1% (Johnson et 
al., 2007). However, in the United States of America the majority of blaCMY-2 gene was carried 
on a IncA/C plasmid (Welch et al., 2007). The prevalence of repA/C plasmids is low but when 
antimicrobial selective pressure is active it can became more prevalent (Winokur et al., 
2001). These large plasmids have been detected in Enterobacteriaceae family and in other 
gram-negative bacteria (Call et al., 2010), from human and animal origin isolates, such as 
beef, chicken  (Winokur et al., 2001). 
 
Overall, PBRT demonstrated that is a good method for detecting replicon types in plasmids 
allows tracing their diffusion and detecting the mobilization capacity of a different gene 
among plasmids (Hopkins et al., 2006). However this scheme still has some limitations, since 
the classification is currently based on plasmids belonging to the 18 of the 26 known Inc 
groups and novel replicons cannot be identified (Carattoli, 2009; Lindsey, Fedorka-Cray, 
Frye & Meinersmann, 2009). This fact may explain why plasmids from one E. coli isolate and 
one Klebsiella pneumoniae in our study were considered “non-typeable”. The most precise 
method to analyse plasmids is based on  the determination of the full-length DNA sequence, 
and so far more than 800 plasmids from Gammaproteobacteria have been fully sequenced 
(http://www.ncbi.nlm.nih.gov/genome/), contributing to the identification of novel plasmid 
families (Carattoli, 2009). 
 
Since these plasmids are very common in Enterobacteriaceae a further typing scheme has 
been proposed, using pMLST (García-Fernández et al., 2008). IncI1 plasmids carrying 
AmpC have been described recently in E. coli and Salmonella (Hopkins et al., 2006). The 






of  bacterial pathogens which represents a crucial factor for the positive selection of these 
plasmids (Kim & Komano, 1997). Briefly, the pMLST method involved PCR amplifying  and 
sequencing genes essential for replication and maintenance, which include: pill, a gene 
within the pil locus involved in pilus biogenesis; sogS, a primase involved in discontinuous 
plasmid DNA replication; ardA, encodes a type-I restriction enzyme, repI1, the RNAI 
antisense regulating system in the IncI1 replication system and the intragenic trbA- pndC 
region involved in maintenance and plasmid transfer respectively (García-Fernández et al., 
2008). The IncF family contains a varied group of plasmids, whose relatedness and 
nomenclature are often complex. One peculiar feature is that IncF plasmids are limited by 
host to the family Enterobacteriaceae and rely on both self-encoded and host-encoded 
factors for duplication. IncF plasmids need DNA gyrase, DnaB, DnaC, DnaG, single strand 
binding and DNA polymerase III proteins for their replication. Since the IncF plasmids are 
considered to be heterogeneous in size and carry multiple replicons,  pMLST allows the 
characterization into homogenous groups according to their phylogenetic relatedness  (Villa, 
García-Fernández, Fortini & Carattoli, 2010). IncF plasmid contains the FII replicon which is 
regulated by CopA, a constitutively synthesized 90 antisense-RNA, which is usually silent. 
The copA region of the FII replicon is involved in the control of replication and incompatibility 
beghvaiour. FIA and FIB replicons are regulated by iterons, in cis-negative binding sites of 
the replication protein RepA and RepB respectively (Villa, García-Fernández, Fortini & 
Carattoli, 2010). Plasmid multilocus sequence typing (pMLST) in our study was performed to 
characterize IncFII, IncI1, plasmids, however it can be used also to characterize also IncN 
and IncHI2 plasmids (García-Fernández et al., 2008).  
 
Within replicon type I1 using the pMLST (http://pubmlst.org/plasmid/) we determined that 
these plasmids belonged to sequence type ST-2 (n= 3; 50%), and the remaining 3 (n= 3; 
50%) were considered non-typeable. These results have been previously shown in  E. coli 
repI1 plasmids harbouring blaCMY-2 isolated from dogs in Italy (García-Fernández et al., 
2008). RepFII were characterized as F2;FIA-;FIB- according to the formula (FII; FIA; FIB). 
 
The resistance among Enterobacteriaceae to β-lactams is increasing both in humans and 
animals and there is no specific β- lactamase that is restricted only to animals or humans 
because most of them have been reported in both (Trott, 2012). This fact is interesting and 
not very surprising since we share the same environment and the β-lactams are widely used 
whether in veterinary medicine whether in human facilities (Pitout, Nordmann, Laupland & 
Poirel, 2005). Overall, the results obtained by the PBRT indicates a high prevalence of some 
replicon types, such as repF, repI and repA/C associated with important resistance genes, 






acquired indirectly, through the transfer of resistance genes from bacteria of animal origin to 
humans. Some studies have pointed out that the possibility of this type of transfer. Winokur 
(2001) refers to the possibility of CMY-2 producing  E. coli transference between animals and 
humans due to the association with ISEcp1 (Winokur et al., 2001; Naseer et al., 2010). Large 
plasmids, carrying resistance genes and transfer-associated genes, may be potential factors 





































5. Conclusion and further studies 
 
The results of the study regarding antimicrobial use indicate that widespread of broad 
spectrum antimicrobials was observed in both dogs and cats, as antimicrobials deemed as 
critically important in human medicine. Overall, antimicrobial use in companion animals was 
according to guidelines implemented in other countries and to previous studies performed. 
However, part of the antimicrobial use may be inadequately justified, and there is a need for 
further surveys about indication-based use of antimicrobials in veterinary medicine. The 
introduction of antimicrobial use guidelines has been shown to lead to more appropriate use 
of antimicrobials, because it could reduce prescribing errors leading to more prudent 
antimicrobial use, and is therefore recommended. 
This study has also revealed the occurrence of plasmid mediated AmpC β-lactamase 
producing strains in clinically important bacterial isolates. Clinical laboratories should test 
FOX-resistant isolates for the presence of pAmpC enzymes, in order to improve detection of 
this emerging resistance phenotype. Since AmpC β-lactamase production is frequently 
associated with multidrug resistance, the dissemination of this AmpC β-lactamase encoding 
plasmids may facilitate the spread of resistance genes, such as blaCMY-2 among different 
members of Enterobacteriaceae. To analyse the potential zoonotic transmission of pAmpC to 
humans, further research would be necessary to confirm this association.  
In summary, this work highlights the importance of monitoring antimicrobial usage, in order to 
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Annex 1 – Critically important antimicrobial classes in veterinary and Human Medicine 
(adapted from Mateus et al., 2011; World Organization for animal Health [OIE], 2007; WHO, 
2007). 
 
 Critically important antimicrobial classes 
Veterinary Human 
Aminoglycosides Aminoglycosides 
Cephalosporins (first to fourth generation) Carbapenems 
Macrolides 



















Annex 2 – Characteristics of CMY and CTX-M β-lactamases and their encoding genes increasingly reported in animal-derived bacteria 
(adapted from Li, X.-Z., Mehrotra, Ghimire, & Adewoye, 2007). 
 
 
 CMY CTX-M 
Bacterial species  E. coli and Salmonella spp. E. coli, Salmonella spp. and other enteric Gram-negative bacteria 
Gene location Plasmid-borne Plasmid-borne 
Genetic association Often associated genetically with other antimicrobial 
resistance determinants and transposons/integrons 
Often coexisted with blaTEM-1 or derivatives 
and/or associated with other antimicrobial 
resistance determinants and transposons/integrons 
Molecular class Class C Class A 
Functional group Group 1 Group 2be 
ESBL NO YES 
Substrate profile Penicillin’s and cephalosporins including cephamycins 
and oxyimino-cephalosporins. Not include carbapenems 
Penicillin’s, cephalosporins including oxyiminocephalosporins, 
and monobactams (aztreonam). 
Not include cephamycins and carbapenems 
Inhibitor profile Inhibited by aztreonam and/or cloxacillin, but not by 
clavulanate 






Annex 3 – Survey - Antimicrobial use in companion animals. 
 
Dia Europeu dos Antibióticos - Iniciativa da UE no domínio da saúde 
 
Todos os anos, a 18 de Novembro, celebra-se o Dia Europeu dos Antibióticos. 
Relembram-se os riscos associados ao uso inadequado de antibióticos e de 
informação sobre o uso racional dos mesmos. 
 
A OMV associa-se a esta iniciativa da União Europeia pedindo a colaboração a todos 
os seus membros no estudo “Utilização de Antibióticos em Animais de Companhia 
em Portugal”.  
 
Este estudo está a ser efetuado na Faculdade de Medicina Veterinária da 
Universidade Técnica de Lisboa e conta com a colaboração da OMV. Tem por objeto 
determinar os hábitos de prescrição de antibióticos dos Médico-Veterinários a exercer 
Clínica de animais de companhia em Portugal.  
 
 
Por favor, clique no link e preencha o inquérito on-line! 
https://www.surveymonkey.com/s/Y59WD96 
 

























Antimicrobianos em Portugal, qual a nossa realidade 
Consumo de Antibióticos 
A- Informação Geral 




o Feminino   
 
3- A sua atividade profissional é exercida em: 
o Consultório Veterinário 
o Clínica Veterinária 
o Hospital Veterinário 
o Outro, por favor, especifique: 
 




5- Há quanto tempo exerce a profissão (anos): 
 
6- Possui especialização ou pós graduação: 
o Sim. Em que área? 
o Não 
7- Endereço de correio eletrónico:* 
Utilização de antibióticos em animais de companhia, 
em Portugal.  
OBJETIVO: através de um questionário sucinto para clínicos Veterinários obter informações no 
que respeita à utilização de antibióticos em animais de companhia Portugal. O tempo estimado 
necessário para completar este questionário é de aproximadamente 10 minutos. Todos os dados 
recolhidos no questionário serão tratados de forma confidencial e anónima. 
 
*Os inquiridos que pretendam ser informados sobre os resultados e conclusões do estudo deverão para o 
efeito indicar o endereço de correio eletrónico.  
O presente questionário apresenta 3 seções. A seção A consiste em informação geral sobre o Médico 
Veterinário; a seção B compreende a caracterização da prescrição de antibióticos; a seção C, consiste em 
determinar qual o antibiótico utilizado para determinada doença. 
Dia Europeu dos Antibióticos – 18 de Novembro.  
A OMV associa-se a esta iniciativa da União Europeia pedindo a 




































B- Caraterização do uso de antibióticos em Centros de atendimento Médico-
Veterinário 
1 - Qual a espécie animal que se apresenta mais frequentemente a consultas: 
o Cão 
o Gato 
o Outra, por favor, especifique: 
 
2- Com que regularidade prescreve antibióticos num dia normal no seu trabalho: 
o Sempre 
o Frequentemente 




3- Com que frequência prescreve antibióticos de forma empírica, sem diagnóstico confirmado: 
o Sempre 
o Frequentemente 




4- Qual a frequência com que realiza cultura bacteriana e testes de suscetibilidade antes da 
prescrição de antibióticos: 
o Sempre 
o Frequentemente 
o Algumas vezes 
o Raramente 
o Nunca 
5- Com que frequência pesa  os animais antes da prescrição de antibióticos: 
o Sempre 
o Frequentemente 
o Algumas vezes   



























Consumo de Antibióticos 










8- Indique os cinco antibióticos que prescreve com maior frequência para cães: (1-mais frequente; 5-
menos frequente) 
o Penicilina G 
o Ampicilina 
o Amoxicilina 











o Outro, por favor especifique:  
 
9- Indique os cinco antibióticos que prescreve com maior frequência para gatos: (1-mais frequente; 5-
menos frequente) 
o Penicilina G 
o Ampicilina 
o Amoxicilina 









































10- Assinale qual /quais os fatores que considera aquando da escolha do antibiótico: 
 Características do dono (económicas, compliance) 
 Caraterísticas e comportamento do animal  
 Modo de ação do antibiótico, se é bacteriostático ou bactericida 
 Farmacocinética/ Farmacodinâmica 
 Espectro de ação 
 Via de administração 
 Baseado em testes de suscetibilidade 
 Infeção aguda/crónica 
 Agente patogénico envolvido 
 Experiência clínica 
 Opinião de colegas 




Para complementar este estudo, e obter informação mais detalhada sobre os hábitos de 
prescrição de antibióticos, agradecíamos que indicasse para as doenças referidas a seguir 
































C- Caraterização da prescrição de antibióticos relativos às doenças mais 
prevalentes 
11- Selecione para cada doença qual ou quais os antibióticos, que utiliza com maior frequência 
11.1- Doenças de pele 









Abcesso/Trauma Otite bacteriana 
CÃO CÃO CÃO GATO CÃO GATO 
Penicilina G o  o  o  o  o  o  
Ampicilina o  o  o  o  o  o  
Amoxicilina o  o  o  o  o  o  
Amoxicilina/Ácido 
clavulânico 
o  o  o  o  o  o  
Cefalexina o  o  o  o  o  o  
Cefovecina o  o  o  o  o  o  
Enrofloxacina o  o  o  o  o  o  
Marbofloxacina o  o  o  o  o  o  
Pradofloxacina o  o  o  o  o  o  
Doxiciclina o  o  o  o  o  o  
Gentamicina o  o  o  o  o  o  
Clindamicina o  o  o  o  o  o  
Trimetropim-
sulfonamida 
o  o  o  o  o  o  
Metronidazol o  o  o  o  o  o  
Florfenicol o  o  o  o  o  o  

































































11- Selecione para cada doença qual ou quais os antibióticos, que utiliza com maior frequência: 
11.2- Aparelho Génito-urinário 













CÃO GATO CÃO GATO CÃO  GATO GATO  CÃO CÃO  
Penicilina G o  o  o  o  o  o  o  o  o  
Ampicilina o  o  o  o  o  o  o  o  o  
Amoxicilina o  o  o  o  o  o  o  o  o  
Amoxicilina/ Ácido 
clavulânico 
o  o  o  o  o  o  o  o  o  
Cefalexina o  o  o  o  o  o  o  o  o  
Cefovecina o  o  o  o  o  o  o  o  o  
Enrofloxacina o  o  o  o  o  o  o  o  o  
Marbofloxacina o  o  o  o  o  o  o  o  o  
Pradofloxacina o  o  o  o  o  o  o  o  o  
Doxiciclina o  o  o  o  o  o  o  o  o  
Gentamicina o  o  o  o  o  o  o  o  o  
Clindamicina o  o  o  o  o  o  o  o  o  
Trimetropim- 
sulfonamida 
o  o  o  o  o  o  o  o  o  
Metronidazol o  o  o  o  o  o  o  o  o  
Nitrofurantoina* o  o  o  o  o  o  o  o  o  




o  o  o  o  o  o  o  o  o  
















11- Selecione para cada doença qual ou quais os antibióticos, que utiliza com maior frequência: 
11.3- Aparelho Gastrointestinal 







Enterite  Colite  




GATO CÃO GATO  
Penicilina G o  o  o  o  o  o  o  o  o  
Ampicilina o  o  o  o  o  o  o  o  o  
Amoxicilina o  o  o  o  o  o  o  o  o  
Amoxicilina/ Ácido 
clavulânico 
o  o  o  o  o  o  o  o  o  
Cefalexina o  o  o  o  o  o  o  o  o  
Cefovecina o  o  o  o  o  o  o  o  o  
Enrofloxacina o  o  o  o  o  o  o  o  o  
Marbofloxacina o  o  o  o  o  o  o  o  o  
Pradofloxacina o  o  o  o  o  o  o  o  o  
Doxiciclina o  o  o  o  o  o  o  o  o  
Gentamicina o  o  o  o  o  o  o  o  o  
Clindamicina o  o  o  o  o  o  o  o  o  
Trimetropim- 
sulfonamida 
o  o  o  o  o  o  o  o  o  
Metronidazol o  o  o  o  o  o  o  o  o  
Neomicina* o  o  o  o  o  o  o  o  o  
Não uso terapêutica  
 
o  o  o  o  o  o  o  o  o  








































11- Selecione para cada doença qual ou quais os antibióticos, que utiliza com maior frequência: 
11.4- Aparelho Músculo-esquelético 






CÃO GATO CÃO GATO CÃO GATO CAO GATO 
Penicilina G o  o  o  o  o  o  o  o  
Ampicilina o  o  o  o  o  o  o  o  
Amoxicilina o  o  o  o  o  o  o  o  
Amoxicilina/ Ácido 
clavulânico 
o  o  o  o  o  o  o  o  
Cefalexina o  o  o  o  o  o  o  o  
Cefovecina o  o  o  o  o  o  o  o  
Enrofloxacina o  o  o  o  o  o  o  o  
Marbofloxacina o  o  o  o  o  o  o  o  
Pradofloxacina o  o  o  o  o  o  o  o  
Doxiciclina o  o  o  o  o  o  o  o  
Gentamicina o  o  o  o  o  o  o  o  
Clindamicina o  o  o  o  o  o  o  o  
Trimetropim- 
sulfonamida 
o  o  o  o  o  o  o  o  
Metronidazol o  o  o  o  o  o  o  o  
Não uso terapêutica  
 

































11- Selecione para cada doença qual ou quais os antibióticos, que utiliza com maior frequência: 
11.5- Aparelho Respiratório 














CÃO GATO CÃO  GATO CÃO GATO CÃO GATO 
Penicilina G o  o  o  o  o  o  o  o  
Ampicilina o  o  o  o  o  o  o  o  
Amoxicilina o  o  o  o  o  o  o  o  
Amoxiciclina/ 
Ácido  clavulânico 
o  o  o  o  o  o  o  o  
Cefalexina o  o  o  o  o  o  o  o  
Cefovecina o  o  o  o  o  o  o  o  
Enrofloxacina o  o  o  o  o  o  o  o  
Marbofloxacina o  o  o  o  o  o  o  o  
Pradofloxacina o  o  o  o  o  o  o  o  
Doxiciclina o  o  o  o  o  o  o  o  
Gentamicina o  o  o  o  o  o  o  o  
Clindamicina o  o  o  o  o  o  o  o  
Trimetropim- 
sulfonamida 
o  o  o  o  o  o  o  o  
Metronidazol o  o  o  o  o  o  o  o  
Não uso 
 terapêutica   





























Annex 4 – Tables with percentage values for all disorders for dogs and cats. 
 
 
Pyoderma dog Deep Pyoderma dog Abscess dog Bacterial otitis Dog Abscess Cat Bacterial otitis Cat
Penicilin G 2% 1% 3% 1% 3% 2%
Ampiciline 1% 1% 1% 1% 1% 2%
Amoxicillin 4% 1% 2% 1% 2% 1%
Amoxicillin-clavulanate 54% 29% 39% 34% 38% 32%
Cephalexin 23% 33% 8% 10% 6% 10%
Cefovecin 3% 4% 2% 1% 3% 3%
Enrofloxacin 5% 17% 16% 23% 23% 28%
Marbofloxacin 1% 4% 4% 10% 5% 9%
Pradofloxacin 0% 2% 3% 1% 4% 1%
Doxycyclin 1% 1% 1% 0% 1% 0%
Gentamicin 0% 0% 0% 12% 0% 9%
Clindamycin 1% 4% 5% 1% 1% 2%
Trimethopim-sulphonamide 1% 0% 0% 1% 0% 0%
Metronidazole 0% 4% 18% 1% 14% 1%
Florfenicol 0% 0% 0% 0% 0% 0%
No therapeutic 4% 0% 0% 2% 0% 2%
Dogs Cats
Skins disorders
UTI Dog UTI complicated Dog Pyelonephrytis Dog Prostatitis Dog Pyometra Dog UTI Cat UTI complicated Cat Pyelonephrytis Cat FLUTD
Penicilin G 0% 1% 1% 1% 0% 0% 1% 1% 0%
Ampiciline 0% 2% 3% 0% 2% 0% 1% 2% 0%
Amoxicillin 3% 1% 3% 2% 2% 3% 1% 3% 2%
Amoxicillin-clavulanate 35% 18% 25% 16% 34% 32% 18% 26% 20%
Cephalexin 9% 13% 13% 6% 9% 7% 13% 13% 7%
Cefovecin 3% 6% 3% 0% 2% 4% 7% 4% 3%
Enrofloxacin 34% 32% 30% 44% 26% 40% 34% 30% 26%
Marbofloxacin 7% 8% 5% 9% 3% 6% 10% 7% 3%
Pradofloxacin 1% 4% 4% 4% 1% 3% 4% 4% 1%
Doxycyclin 2% 3% 1% 1% 2% 2% 3% 1% 0%
Gentamicin 1% 1% 2% 0% 1% 1% 1% 1% 1%
Clindamycin 0% 1% 1% 1% 0% 0% 1% 1% 0%
Trimethopim-sulphonamide 4% 6% 4% 13% 2% 3% 3% 2% 1%
Metronidazole 1% 1% 1% 1% 15% 1% 1% 1% 0%
Nitrofuranoin 0% 0% 1% 1% 0% 0% 1% 0% 1%
Phosfomycin 1% 1% 0% 0% 0% 0% 0% 0% 0%
No therapeutic 1% 1% 3% 1% 3% 1% 1% 3% 35%
Dogs Cats
Urinary tract infections
Acute gastritis dog Periodontal disease dog Chronic gastritis dog Enteritis dog Colitis dog Periodontal disease cat Chronic gastritis cat Enteritis cat Colitis cat
Penicilin G 1% 1% 2% 2% 1% 1% 2% 1% 1%
Ampiciline 1% 1% 4% 6% 3% 1% 3% 6% 2%
Amoxicillin 6% 4% 6% 4% 3% 4% 7% 4% 3%
Amoxicillin-clavulanate 29% 30% 18% 19% 17% 29% 18% 22% 18%
Cephalexin 4% 1% 3% 1% 1% 3% 3% 1% 1%
Cefovecin 7% 3% 0% 1% 1% 8% 0% 1% 2%
Enrofloxacin 9% 7% 4% 8% 6% 6% 3% 8% 6%
Marbofloxacin 0% 1% 0% 1% 1% 1% 0% 1% 1%
Pradofloxacin 1% 3% 0% 0% 0% 3% 0% 0% 0%
Doxycyclin 4% 1% 1% 1% 1% 2% 0% 1% 1%
Gentamicin 1% 1% 2% 2% 1% 1% 1% 1% 1%
Clindamycin 4% 5% 0% 1% 1% 3% 0% 0% 1%
Trimethopim-sulphonamide 1% 1% 2% 9% 8% 1% 3% 6% 6%
Metronidazole 27% 39% 19% 39% 46% 35% 17% 40% 46%
Neomicin 1% 0% 0% 1% 3% 0% 0% 1% 3%











Canine upper respiratory tract disease Tracheobronchitis dog Pneumonia dog Pyothorax dog Feline upper respiratory tract disease Feline respiratory complex Pneumonia cat Pyothorax cat
Penicilin G 1% 1% 2% 2% 1% 1% 2% 2%
Ampiciline 1% 1% 3% 2% 1% 1% 2% 1%
Amoxicillin 4% 5% 1% 1% 4% 3% 2% 1%
Amoxicillin-clavulanate 45% 36% 29% 25% 40% 32% 30% 25%
Cephalexin 8% 8% 12% 12% 8% 7% 12% 12%
Cefovecin 1% 0% 0% 0% 1% 3% 1% 0%
Enrofloxacin 15% 10% 24% 23% 17% 15% 24% 22%
Marbofloxacin 3% 1% 6% 5% 2% 2% 6% 5%
Pradofloxacin 1% 1% 2% 1% 1% 1% 3% 1%
Doxycyclin 16% 29% 9% 2% 21% 28% 12% 2%
Gentamicin 1% 1% 2% 3% 1% 1% 1% 2%
Clindamycin 0% 0% 1% 1% 1% 2% 1% 2%
Trimethopim-sulphonamide 2% 1% 3% 2% 0% 0% 2% 2%
Metronidazole 0% 0% 5% 17% 0% 0% 5% 17%
No therapeutic 2% 5% 0% 2% 2% 5% 1% 2%
Dogs Cats
Respiratory tract diseases
Osteomyelitis dog Exposure fracture dog Pre-surgery dog Osteomyelitis cat Exposure fracture cat Pre-surgery cat
Penicilin G 2% 2% 5% 1% 2% 5%
Ampiciline 1% 1% 2% 1% 1% 2%
Amoxicillin 1% 1% 4% 1% 1% 5%
Amoxicillin-clavulanate 14% 30% 42% 14% 30% 42%
Cephalexin 23% 22% 16% 23% 21% 15%
Cefovecin 3% 2% 3% 4% 2% 3%
Enrofloxacin 13% 15% 4% 15% 15% 4%
Marbofloxacin 2% 1% 1% 2% 2% 2%
Pradofloxacin 1% 1% 0% 1% 1% 0%
Doxycyclin 1% 0% 0% 0% 0% 0%
Gentamicin 2% 1% 1% 2% 1% 1%
Clindamycin 25% 9% 3% 22% 8% 2%
Trimethopim-sulphonamide 2% 2% 0% 1% 2% 0%
Metronidazole 9% 14% 1% 9% 14% 1%



















Abstract of the Oral presentation at the OMV Conference 2012 
 
Etiologia e Detecção de estirpes multiresistentes na infecção do trato urinário 
em cães e gatos em Lisboa, Portugal. 
D. Saial1, A. Belas
1, M. Centeno1, N. Couto1, C. Pomba1.  
1Laboratório de Resistência aos Antibióticos e Biocidas, CIISA, Faculdade de 
Medicina Veterinária, Universidade Técnica de Lisboa, Portugal. 
O objectivo deste estudo foi determinar a etiologia da ITU na comunidade e a 
frequência de agentes patogénicos multirresistentes na região de Lisboa.  
No presente estudo foram isoladas 136 bactérias uropatogénicas, em cães (n=108) 
e em gatos (n=28), durante o período de Janeiro de 2009 até Dezembro de 2011 no 
Hospital Veterinário da Universidade Técnica de Lisboa e em Hospitais e Clínicas 
privadas na área de Lisboa. Os isolados foram identificados por sistemas 
bioquímicos. Os métodos de difusão de disco e painéis de microdiluição DADE 
MicroScan foram utilizados para os testes de susceptibilidade aos antimicrobianos.  
Em cães, Escherichia coli foi o agente uropatogénico mais frequente (52%), seguido 
de Staphylococcus spp. (14%), Proteus spp. (13%), Enterococcus spp. (11%), 
Pseudomonas spp. (4%), Klebsiella spp. (4%), e outros (2%).  Em gatos, Escherichia 
coli foi também o mais frequente (46%), seguido de Staphylococcus spp. (11%), 
Enterococcus spp. (11%), Enterobacter spp. (11%), Pseudomonas spp. (4%), 
Proteus spp. (4%) e outros (13%). Detectaram-se duas estirpes de E. coli produtoras 
de cefalosporinases (pAmpC) e uma enzima β-lactamase de espectro alargado 
(ESBL). Um isolado de Acinetobacter baumannii foi identificado como produtor de 
pAmpC. Dois isolados de Enterococcus spp. susceptíveis à vancomicina exibiram 
um alto nível de resistência à gentamicina (HLGR), sendo um deles resistente à 
ampicilina, fármaco de eleição para a terapêutica da infecção por Enterococcus. 
Dois staphylococci demonstraram resistência à oxacilina e multirresistência a mais 
de 3 classes de antimicrobianos diferentes (Staphylococcus pseudintermedius 
meticilina-resistente – MRSP). 
A detecção de estirpes gram-negativas produtoras de pAmpC, ESBL e estirpes 
gram-positivas como MRSP e Enterococcus com resistência à ampicilina e HLGR é 
extremamente preocupante e com consequências inerentes de limitação terapêutica. 
A presença de bactérias uropatogénicas multirresistentes constitui não só um 
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Different epidemiology of blaCMY-2 plasmids among clinical Escherichia coli 
from companion animals in Portugal and Denmark 
D. Saial1, 2, V. Bortolaia2, A. Belas1, M. Centeno1, N. Couto1, L. Guardabassi2, C. 
Pomba1 
1Interdisciplinary Centre of Research in Animal Health, Faculty of Veterinary 
Medicine, Technical University of Lisbon, Av. Universidade Técnica de Lisboa 1300-
477 Lisbon, Portugal  
2Department of Veterinary Pathobiology, Faculty of Life Sciences, University of 
Copenhagen, Stigbøjlen 4, Frederiksberg C, 1870, Denmark 
Objective: The aim of this study was to compare the epidemiology of CMY-2 β-
lactamase-encoding genes among clinical E. coli from dogs and cats in two 
European countries with different antibiotic use practices. 
Methods: We characterised the blaCMY-2-harbouring plasmids of eight and five E. coli 
collected in 2000-2012 at the veterinary diagnostic laboratories of the Technical 
University of Lisbon and the University of Copenhagen, respectively. Plasmids 
harbouring blaCMY-2 were transferred into GeneHog E. coli by electroporation and 
typed by S1 endonuclease pulsed-field gel electrophoresis, PCR-based replicon 
typing, plasmid multilocus sequence typing (pMLST) and antimicrobial susceptibility 
testing of transformants to detect co-transfer of antimicrobial resistance. 
Results: The eight blaCMY-2-harbouring plasmids from Portugal belonged to two 
distinct incompatibility groups: IncFII/F2:A-:B- of ca. 78 Kb (n=7), and IncA/C of ca. 
140 Kb (n=1). IncFII plasmids encoded additional resistance to ciprofloxacin, 
gentamicin, sulphametoxazole-trimethoprim and tetracyclines. The five plasmids 
from Denmark were all IncI1 ranging from 55 to 104 Kb, were classified as ST2 (n=2) 
and non-typeable (n=3) by pMLST. The Danish plasmids did not co-transfer 
resistance to non-β-lactam antimicrobials. 
Conclusion: Spread of blaCMY-2 was associated with different plasmid types among 
isolates from the two countries, being mainly driven by IncFII encoding a multidrug 
resistance phenotype in Portugal and by IncI1 not associated with multidrug 
resistance in Denmark. Since the plasmid types detected among companion animals 
partially overlap with the types found in humans in the respective countries, further 
studies are needed to determine whether transmission of blaCMY-2 from dogs and cats 
represents a zoonotic risk.   
